OrbiMed

Biopharmaceutical company engaged in developing, manufacturing and commercializing novel biotherapeutics

MDClone Ltd. designs and develops software that analyzes medical records. Its software platform creates synthetic medical records for fictitious patients, avoiding the risk of public disclosure of actual medical data. The company’s platform enables researchers to examine the behavior of the disease, doctors, drugs, and health organizations without risking private patient medical data. MDClone Ltd. was founded in 2016 and is based in Beersheba, Israel.

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company’s second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.

PMV Pharma is developing first-in-class p53 and p53 pathway modulators for the treatment of cancer. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.

Shenzhen Dami He Xiaomi Cultural Broadcast Co., Ltd., doing business as Dami & Xiaomi, operates an online platform for children with autism spectrum. Its platform provides integrated services, such as rehabilitation, education support, parent training, online courses, and science information. The company was founded in 2014 and is based in Shenzhen, China.

SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. SI-BONE, Inc. was founded in 2008 and is headquartered in Santa Clara, California.

Predix is a drug discovery and development company that uses a novel 3D Discovery and Optimization Engine for GPCR drug candidates and is taking its novel compounds into the clinic. The discovery engine uses a sophisticated proprietary algorithm, PREDICT(TM), for computer modeling the 3D structure of any GPCR target; advanced technologies HYPERION(TM) and RISS(TM) for rapid high-throughput in silico screening of millions of compounds against the 3D in silico model of the target; and an integrated medicinal/computational platform for lead optimization based on the receptor's structure (ICELR-3D(TM)) and predictive algorithms for important drug properties. In August, Predix and Physiome Sciences Inc. combined companies and expanded the expertise into ion channel drug discovery.

Vivimed Labs has metamorphosed from a domestic small, entrepreneurial family-operated business to a globally renowned supplier of niche molecules and formulations across Healthcare, Pharmaceuticals and Specialty Chemicals consumers in nearly 50 countries.Driven by our philosophy of using chemistry as a base to create ingredients which touch human life on a day to day basis, Vivimed Labs delivers world-class products across the various segments They serve.

MethylGene Inc. (TSX:MYG) is a publicly-traded, clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics with a focus on cancer. The Company's product candidates include: MGCD265, an oral, multi-targeted kinase inhibitor targeting the Met, VEGF, Ron and Tie-2 receptor tyrosine kinases that is in multiple clinical trials for cancer; MGCD290, a fungal Hos2 inhibitor for use in combination with fluconazole for serious fungal infections which has completed Phase I clinical studies; and mocetinostat (MGCD0103), an oral, isoform-selective HDAC inhibitor for cancer which has been in multiple Phase II clinical trials and is currently in a Phase II trial in refractory or relapsed follicular lymphoma. Mocetinostat is licensed to Taiho Pharmaceutical Co. Ltd in certain Asian countries. A fourth compound discovered using MethylGene's HDAC platform, EVP-0334 - a potential cognition enhancing agent for neurodegenerative diseases has successfully completed Phase I trials sponsored by EnVivo Pharmaceuticals Inc. MethylGene also has a funded collaboration with Otsuka Pharmaceutical Co. Ltd. for applications in ocular diseases using the Company's proprietary kinase inhibitor chemistry.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Its Omnipod System comprise two devices: a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, and its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, and the Middle East. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.

Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.

RayzeBio, Inc. is a biotechnology company that develops tumor-targeted small molecule medicines that harness the power of radioisotopes. The company provides macrocyclic peptide mimetic binders to deliver therapeutic radioisotopes, such as Actinium-225, an alpha-emitter for solid tumors. RayzeBio, Inc. was founded in 2020 and is based in San Diego, California.

Better Continuous Glucose Monitors with a Next-Generation Glucose Sensing Enzyme SmartZyme BioPharma, Inc. is a medical technology company enabling a seamless leap to better performing glucose monitoring for people with diabetes. The company is accelerating the integration of SmartZyme's next-generation glucose-sensing enzyme into continuous glucose monitoring devices. A next-generation enzyme means no more signal mediators for the most cost-effective manufacturing; no more hypoglycemic errors for a superior safety profile; and no more fingersticks for the best quality of life. SmartZyme is an OrbiMed portfolio company.

Asian Institute of Medical Sciences is a 425 bedded super specialty hospital in Delhi NCR, India which is dedicated to provide accessible, affordable and best available healthcare services in India. Accredited by NABH and NABL, Asian Hospital Faridabad provides preventive, diagnostic, therapeutic, rehabilitative, palliative and supportive services all under one roof and is designed to meet patient care and research requirements of the new millennium. Asian Institute of Medical Sciences offers comprehensive multi-specialty tertiary care facilities through its 14 centres of excellence. - ASIAN CANCER CENTRE - ASIAN CENTRE FOR BONE MARROW TRANSPLANT - ASIAN HEART CENTRE - ASIAN CENTRE FOR ADVANCED SURGERY - ASIAN CENTRE FOR NEUROLOGY AND NEUROSURGERY - ASIAN CENTRE FOR UROLOGY AND KIDNEY TRANSPLANT - ASIAN CENTRE FOR RENAL DISEASES - ASIAN CENTRE FOR BONE AND JOINTS - ASIAN CENTRE FOR ADVANCED IMAGING - ASIAN CENTRE FOR GASTROENTEROLOGY - ASIAN CENTRE FOR MOTHER AND CHILD - ASIAN CENTRE FOR BARIATRIC & METABOLIC SURGERY - ASIAN CENTRE FOR AESTHETIC SURGERY & MEDICINE - ASIAN IVF CENTRE

Prothelia is a US based private biotech company founded in 2007. Prothelia’s lead program is a novel protein therapy for the treatment of congenital muscular dystrophy type 1A, a rare disease affecting approximately 4,000 patients.

Born from the founders’ recognition that their diverse but complementary skills and experiences would enable them to successfully address challenges that others had not, the company set about solving a vexing problem: how to bring true proteomics to the world in a way that accelerates therapeutic development, dramatically improves medical diagnostics, and makes personalized and predictive medicine a reality. The extraordinary team at Nautilus represents a wide spectrum of disciplines and expertise, including protein chemists, chip designers, molecular biologists, data scientists, material scientists, biophysicists, optical engineers, microfluidics engineers, bioinformaticists, software engineers, and more. Nautilus is positioned to revolutionize proteomics, transform the way drugs are developed, and significantly improve the way human health is managed.

Carrot offers a fertility benefit for modern companies, focused on making fertility care easier, accessible, and more affordable. The company partners with modern companies to provide fertility coverage for the millions of employees. Through its software, Carrot helps employees to personalize a fertility plan, chat with fertility experts, order medications, and access unique content. It helps them access the care they need, such as egg freezing, in-vitro fertilization, fertility diagnoses, and more.

Unum Therapeutics uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer. Unum’s lead program, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, is expected to enter Phase I clinical testing in the coming months to assess safety and efficacy. Unum is seeking partners interested in using the ACTR technology to arm proprietary tumor-specific antibodies with a T-cell to improve their therapeutic potential. The company is headquartered in Cambridge, MA.

Jinxin Fertility Group Limited provides assisted reproductive services (ARS) in China and the United States. The company primarily offers its patients with two treatment solutions, including artificial insemination, which can be performed with either husband’s sperm or a donor sperm; and IVF technology, whereby fertilization is achieved through conventional in vitro fertilization and embryo transfer or IVF with intracytoplasmic sperm injection. It also provides related services, such as nutrition guidance, Chinese medicine treatment, and psychological counseling to support the ARS. In addition, the company offers management services; medical services in the areas of gynecology, urology, and internal medicine; ambulatory surgery centre facilities services; and ancillary medical services. Jinxin Fertility Group Limited was founded in 2003 and is headquartered in Chengdu, China.

InventisBio is a biotech company whose product pipeline includes small molecule drug candidates for targeted therapies in lung cancer, breast cancer and gout. The company is also actively developing drugs that can be combined with other immune-oncology targeted therapies, such as PD-1 antibody, for various cancer indications. The company is co-founded by Dr. Yaolin Wang and other scientists who have previously worked at Merck and Schering-Plough, leading various drug discovery projects in oncology, metabolic and infectious disease areas.

Invitae is a genetic information company whose mission is to bring genetic information into routine medical practice to improve the quality of healthcare for billions of people. Specializing in genetic diagnostics for hereditary disorders, Invitae is aggregating the world’s genetic tests into a single service with better quality, faster turnaround time, and a lower price than most single-gene diagnostic tests today. What’s our plan? It takes three steps: --Make genetic testing more affordable and accessible than ever before. --Build a secure and trusted genome management infrastructure. --Design a new global community for sharing genetic information to advance science and medicine. Today, we are reinventing genetic testing by lowering the barriers for clinicians and patients to obtain diagnostic genetic information. Together we can improve healthcare for billions of people.

Laxmi Dental Export Private Limited operates a dental laboratory that specializes in providing dental products and services. The company manufactures prosthodontics and dental cosmetic products, such as porcelain fused to metals, restoration dental materials, ceramic restorations, implant systems, composites, and cast partial dentures. It serves laboratories and dentists worldwide. The company was incorporated in 2004 and is based in Mumbai, India.

TigerConnect is a provider of clinical communication solutions, TigerConnect helps physicians, nurses, and other staff communicate and collaborate more effectively, accelerating productivity, reducing costs, and improving patient outcomes. Trusted by more than 4,000 healthcare organizations, TigerConnect maintains 99.99% uptime and processes over 10 million messages each day. Its category-leading product innovations and advanced integrations with critical hospital systems deliver high value for hospitals and large health systems. Their commitment to client success is reflected in their broad support organization that works directly with clients at every stage to streamline communication workflows and achieve the highest possible ROI. The company was incorporated in 2010 and is headquartered in Santa Monica, California.

Garuda Therapeutics is developing off-the-shelf hematopoietic stem cell (HSC) therapies to treat a broad range of severe and life-threatening diseases.

Dimension Therapeutics is a gene therapy company focused on developing novel treatments for rare diseases. Their team comprises biotech industry veterans and thought leaders in gene therapy and rare diseases. The company is focused on advancing its platform of gene therapy programs in rare diseases through clinical development, starting with lead programs in hemophilia, and building out a world-class product engine for adeno-associated virus (AAV) therapeutics. In conjunction with its launch, Dimension has entered into an exclusive license and collaboration with REGENX Biosciences. REGENX holds exclusive rights to a portfolio of over 100 patents and patent applications pertaining to its NAV vector technology and related applications. Through its license and collaboration with REGENX, Dimension has acquired preferred access to NAV vector technology and rights within REGENX product programs in multiple rare disease indications. Dimension has completed a Series A financing led by Fidelity Biosciences.

iECURE is a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet needs.

Owlet Baby Care Inc. develops and manufactures a monitor that tracks babies breathing and heart rate. It offers Owlet Smart Sock, a monitoring product that sends alerts to the base station when babies stop breathing while sleeping. The company’s monitor is compatible with iOS and Android devices. It sells its products online. Owlet Baby Care Inc. was founded in 2012 and is based in Lehi, Utah.

Adaptimmune develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroys cancerous or infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was incorporated in 2007 and is based in Abingdon, United Kingdom.

MBX Biosciences is a biotechnology company that develops therapies to treat rare endocrine diseases where there is inadequate treatment available. It focuses on the discovery, development, and commercialization of first-in-class endocrine therapeutics. The company was founded in 2018 and headquartered in Carmel, Indiana.

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.

Silverback Therapeutics is a biopharmaceutical company that develops ImmunoTAC therapies targeting previously inaccessible disease pathways. They developing a new generation of systemically delivered, locally active therapies that potently modulate fundamental disease pathways once deemed inaccessible. Silverback Therapeutics is building a platform technology capable of unlocking potent immuno-modulatory pathways using an established antibody-guided approach for targeting disease sites. The company's proprietary ImmunoTAC technology and integrated R&D approach enables the design of product candidates that can be administered systemically, but that act only at the sites of disease.

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in phase II clinical trial for the treatment of frontotemporal dementia disease; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. The company also offers AL002 and AL003, which are in phase 1b clinical trial for the treatment of Alzheimer’s disease. In addition, it has 10 programs under research and development stage. The company has a collaboration agreement with Adimab, LLC for the research and development of antibodies. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.

BlossomHill Therapeutics, Inc. is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders.

CBT Pharmaceuticals is an emerging life sciences oncology company focused on developing innovative medicines targeting the growth and proliferation of cancer cells for which available treatments are inadequate. Our pipeline is comprised of four development-stage assets – an oral agent that specifically targets cancer metastasis, a pre-clinical candidate that targets uncontrolled growth signaling pathways, and two investigational products that restore the body’s immune system to recognize and kill cancer cells.

Theseus Pharmaceuticals is a Technology based company.

Sonendo developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science®. The GentleWave® System shows significant improvements in clinical efficacy and practice efficiency when compared to standard root canal treatment.1,2, 3 Sonendo is the parent company of TDO® Software, the developer of the most widely used endodontic practice management software in the world, designed to simplify practice workflow. TDO software seamlessly integrates practice management, imaging, social media, referral reporting, CBCT imaging, and offers built-in communication with the GentleWave System.

GENEWIZ is a leading global genomics service company. A full-service provider, GENEWIZ provides DNA sequencing, gene synthesis, molecular biology, next generation sequencing, bioinformatics, and GLP regulatory services. From the company’s founding, GENEWIZ has maintained its unwavering commitment to providing customers with the best value. Excelling in both science and customer support, GENEWIZ is dedicated to accelerating scientific discovery, as well as to developing and delivering innovative solutions for translational medicine and healthcare. Easily accessible around the world, GENEWIZ is the preferred partner at leading academic, pharmaceutical, biotechnology, agricultural, government, and clinical institutions. At GENEWIZ, it is their mission to contribute to the advancement of life sciences and technologies. Together with their clients, they can make a difference in the pursuit of scientific discoveries, better healthcare, a greener environment, and abundant food supplies. Their goal is to be the best in the world and the best for the world. Headquartered in South Plainfield, NJ, GENEWIZ is a privately-held global enterprise with locations in Boston, MA; Washington, DC Metro; Research Triangle Park, NC; San Diego, CA; Los Angeles, CA; San Francisco, CA; and Seattle, WA. International locations include Beijing, China; Suzhou, China; London, United Kingdom; Langen, Germany; and Tokyo, Japan.

Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief. Q32 Bio consists of a team of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies.

Alpine Immune Sciences is an immunotherapy startup focused on developing recombinant, protein-based therapeutic solutions. It was founded on January 23, 2015, and is based in Seattle, Washington, United States.

Ornim, Inc. develops medical monitoring tools for the measurement of blood flow and oxygen saturation in patients. The company offers CerOx, a non-invasive monitor, which provides real-time data on oximetry and blood flow measurements of specific tissue. Its products are used for applications in neurological treatments and cardiac surgery. The company was founded in 2004 and is based in Santa Clarita, California. It has a research and development subsidiary operation in Israel.

Recode Therapeutics, Inc., a biopharmaceutical company, develops precision medicines for pulmonary diseases. Its pipeline includes programs for primary ciliary dyskinesia and nonsense mutations in cystic fibrosis. The company’s non-viral lipid nanoparticle platform enables the delivery of various payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. Recode Therapeutics, Inc. was founded in 2015 and is based in Menlo Park, California.

Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company’s lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson’s disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.

Adicet Bio is a pre-clinical stage biotechnology company engaged in the design and development of cutting-edge allogeneic immunotherapies for cancer and other diseases.

Turnstone Biologics Inc., a biotechnology company, focuses on the development of viral immunotherapies to improve survival of people with cancer. Its lead candidate RIVAL-01 consists of the vaccinia virus backbone encoding three potent immunomodulators, such as Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine designed to work together to drive immune activity and re-program the microenvironment to be best suited for tumor eradication. The company was founded in 2015 and is based in Ottawa, Canada with an additional office in New York, New York.

As of March 13, 2019, Arsanis, Inc. was acquired by X4 Pharmaceuticals Inc., in a reverse merger transaction. Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases in the United States. The company engages in the development of ASN500, a mAb that is in preclinical development targeting respiratory syncytial virus (RSV), a virus that can cause respiratory tract infections in young children and elderly, and immunocompromised patients. Its pipeline also comprises mAbs targeting various serious bacterial and viral pathogens, including Staphylococcus aureus and RSV. In addition, the company’s preclinical stage Gram-negative mAb programs include ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

ChemomAb is a clinical stage biopharmaceutical company, founded in 2011. ChemomAb specializes in the development of proprietary monoclonal antibodies, directed towards novel targets, for the treatment of immune-mediated and fibrotic disorders including orphan indications. The leading compound, CM-101, was selected after meticulous testing in a series of pre-clinical animal models simulating human disorders and has shown promising safety and efficacy as well as a novel mechanism of action.

Atox Bio is a biotechnology company that specializes in infectious diseases, immunomodulators, and critical care.It focuses on novel modulators of the immune response that target key multiple and interrelated pathways of both the adaptive and innate immune response that play critical roles in infectious and inflammatory diseases as well as ischemia/reperfusion injuries. The company was founded in 2003 and headquartered in HaMerkaz, Israel.

Agensys a biotechnology company, engages in the research and development of therapeutic human monoclonal antibodies and antibody drug conjugates for the treatment of cancer. It offers products to treat various tumors, as well as prostate, pancreatic, and bladder cancers. The company, formerly known as UroGenesys, was founded in 1997 and is based in Santa Monica, California. As of December 18, 2007, Agensys, Inc. operates as a subsidiary of Astellas Pharma US, Inc.

Disc Medicine is led by an experienced team of scientists and industry experts, and supported by a panel of advisors with a strong track record of discovering and developing new and innovative therapies. Disc Medicine was founded by Atlas Venture and Brian MacDonald, with Novo Ventures and Access Biotechnology joining as additional investors.

Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations. The company has developed a compound to cure the lung disease in cystic fibrosis patients carrying a specific splicing mutation. It is also developing a targeted modulation approach to correct the splicing pattern of CFTR transcripts according to the specific mutation carried.

Crossover Health, Inc. provides workplace healthcare services for employers and employees in companies. It offers primary, ancillary, and advanced services, including urgent care, preventive care, chronic disease management, health risk assessment, health education, health coaching, biometrics, physical therapy, chiropractic, acupuncture, specialist preferred network, care coordination, health analytics, and remote care. The company was founded in 2010 and is headquartered in Aliso Viejo, California with health centers in Silicon Valley, as well as in other locations in the United States.

Synthorx, Inc., a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor. It also develops IL-2 Synthorin for autoimmune indications; IL-10 Synthorin, a naturally occurring immune cell growth factor in humans for the treatment of immuno-oncology (IO); and IL-15 Synthorins, an immunoregulatory cytokine to treat IO. In addition, the company develops other Synthorin programs targeting undisclosed cytokines that play critical roles in the orchestration of anti-tumor responses by innate and adaptive immune cells. The company was formerly known as Alinos, Inc. and changed its name to Synthorx, Inc. in March 2014. Synthorx, Inc. was founded in 2014 and is headquartered in La Jolla, California. As of January 23, 2020, Synthorx, Inc. operates as a subsidiary of Sanofi.

ViewRay, Inc. designs, manufactures, and markets radiation therapy systems. The company offers MRIdian, a magnetic resonance image guided radiation therapy system to image and treat cancer patients. Its MRIdian integrates MRI technology, radiation delivery, and proprietary software to see the soft tissues, shape the dose to accommodate for changes in anatomy, and strike the target using real-time targeting throughout the treatment. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. markets its MRIdian through a direct sales force and distribution network. It has operations in the United States, France, Germany, and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

Nabriva Therapeutics AG operates as a biopharmaceutical company that engages in the discovery and development of antibiotics for use in community and hospital infections. The company focuses on antibiotic classes, such as pleuromutilins designed for oral and topical application; and injectable broad-spectrum anti-MRSA cephalosporins. Its products include Oral Pleuromutilins BC-3205 and BC-3781 for multi-drug resistant (MDR) pathogens, including methicillin resistant Staphylococcus aureus (MRSA), MDR Streptococcus pneumonia, and vancomycin resistant Enterococcus faecium; Topical Pleuromutilin BC-7013 for the treatment of various bacterial associated, or derived dermatological diseases; and Cephalosporins for the treatment of hospital infections. The company was formerly known as Antibiotic Research Institute and changed its name to Nabriva Therapeutics AG in February, 2006. Nabriva Therapeutics AG was founded in 2001 is based in Vienna, Austria.

Amarin Corporation is a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease. Amarin’s lead candidate, AMR101, is currently being studied in two concurrently run pivotal Phase 3 trials. These trials are investigating the efficacy of AMR101 in lowering triglycerides in patients with very high triglycerides (>500mg/dl) and in patients with mixed dyslipidemia who are taking statins. Amarin’s cardiovascular programs capitalize on Amarin's expertise in the field of lipid science and the known therapeutic benefits of essential fatty acids in treating cardiovascular disease. Amarin is headquartered in Dublin, Ireland, and has its research and development headquartered in Mystic Connecticut, USA. Amarin is listed in the U.S. on NASDAQ (ticker: AMRN)

Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer. The company's immunotherapies harness the immune system to destroy cancer cells that target truncal tumor neo-antigens and flags to the immune system present on the surface of every cancer cell, enabling scientists to target and destroy tumors without harming healthy tissues.

Æglea BioTherapeutics is a biotherapeutic company exploiting the amino acid (AA) dependencies of many tumors by developing novel, human-derived AA-degrading enzymes that have been engineered to have optimized catalytic and biopharmaceutic properties. The metabolic basis of tumor amino acid dependence is fundamentally different from the nutritional needs of normal tissues, creating a vulnerability to selective killing for tumor cells. The company was founded in 2013 and is headquartered in Austin, Texas.

Otic Pharma is a clinical-stage pharmaceutical company focusing on the development and commercialization of products for disorders of the ear, nose, and throat (ENT). The company has two platform technologies, each of which has the potential to be developed for multiple ENT indications. The company is currently developing a nasally-administered, combination drug product (OP-02) intended to address the underlying cause of otitis media and Eustachian tube dysfunction (OM/ETD), a condition that affects more than 700 million people around the world every year. Otitis media is one of the most common disease seen in pediatric practice and the most frequent reason children consume antibiotics or undergo surgery. The company also has a foam-based drug delivery technology platform (OP-01) that can be used to deliver drugs into the ear, nose, and sinus cavities. The company is currently developing OP-01 as an improved treatment option for acute otitis externa (“swimmers ear”). For more information on the company, please visit www.oticpharma.com

Predix is a drug discovery and development company that uses a novel 3D Discovery and Optimization Engine for GPCR drug candidates and is taking its novel compounds into the clinic. The discovery engine uses a sophisticated proprietary algorithm, PREDICT(TM), for computer modeling the 3D structure of any GPCR target; advanced technologies HYPERION(TM) and RISS(TM) for rapid high-throughput in silico screening of millions of compounds against the 3D in silico model of the target; and an integrated medicinal/computational platform for lead optimization based on the receptor's structure (ICELR-3D(TM)) and predictive algorithms for important drug properties. In August, Predix and Physiome Sciences Inc. combined companies and expanded the expertise into ion channel drug discovery.

Enobia develops therapies to treat serious genetic bone disorders for which there are no approved treatments.

Cyrus Biotechnology builds software tools to accelerate basic research in biotech, pharma, and industrial biotechnology. Cyrus Bench delivers an enterprise version of the Rosetta molecular modeling and design toolkit, with the associated array of bio-molecular computation tools. It was founded in 2014 and headquartered in Seattle, Washington.

Nutrinia is a neonatology company developing pharmaceuticals to treat rare conditions of the gastrointestinal tract. Our current products in development are oral formulations of insulin shown to enhance adaptation and rehabilitation of the gut in infants. We at Nutrinia live by the belief that science is best used to make life better for people, especially the most vulnerable populations.

Biodel Inc. (Biodel) is a development-stage company. The Company is a biopharmaceutical company focused on the development and commercialization of treatments for diabetes. It develops its product candidates by applying its formulation technologies to existing drugs. Its product candidate is Linjeta. It has formulated Linjeta as rapid-acting mealtime insulin for the treatment of patients with Type I and Type II diabetes. Earlier stage product candidates include follow-on and second generation rapid-acting mealtime insulins or insulin analogs, VIAtab, a sublingual tablet formulation of insulin, a line of basal insulins, and a formulation of glucagon.

Gemini Therapeutics is a precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases.Their therapeutic candidates are matched to molecular abnormalities found in patients with high clinical need and our broad multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. Launched with funding from leading life science investors and powered by academic partnerships around the world,they are developing a series of potentially first-in-class therapeutics.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in Phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in phase II clinical trial for the treatment of frontotemporal dementia disease; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. The company also offers AL002 and AL003, which are in phase 1b clinical trial for the treatment of Alzheimer’s disease. In addition, it has 10 programs under research and development stage. The company has a collaboration agreement with Adimab, LLC for the research and development of antibodies. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.

ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of cystic fibrosis. They have combined selected tRNAs with their unique and diverse proprietary delivery platforms to create and develop first-in-class suppressor tRNA-nanoparticle therapeutics for correcting nonsense mutations. ReCode’s diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF). The company’s proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing. The company was founded in 2015 and is based in Dallas, Texas.

MacroGenics, Inc., a biotechnology company, focuses on the development, manufacture, and commercialization of immunotherapeutics for autoimmune disorders, cancer, and infectious diseases. The company is developing immune-based products, including monoclonal antibodies; and vaccines to prevent infections in healthy individuals. The company's Fc engineering technology enables to improve antibody functions to eliminate cancer cells. It is also developing products around the Dual Activating ReTargeting technology. The company was founded in 2000 and is headquartered in Rockville, Maryland.

Innovative Spinal Technologies is a spine technology company that develops motion preservation and minimally invasive treatments for spinal disorders. Its products include AXIENT Dynamic Fixation system, a pedicle screw-based motion system, PARAMOUNT Lumbar Fusion System, which is engineered for lumbar fusion procedures conducted in a minimally invasive, mini-open, or open fashion, PARAMOUNT MIS Pedicle Screw System for single and multi-level procedures, PARAMOUNT Open Pedicle Screw System, which is designed to meet the needs of minimally invasive lumbar fusion, and PARAMOUNT VBR, which is designed for a minimally invasive transforaminal approach. Innovative Spinal Technologies was founded in 2002 and is headquartered in Mansfield, Massachusetts

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in phase II clinical trial for the treatment of frontotemporal dementia disease; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. The company also offers AL002 and AL003, which are in phase 1b clinical trial for the treatment of Alzheimer’s disease. In addition, it has 10 programs under research and development stage. The company has a collaboration agreement with Adimab, LLC for the research and development of antibodies. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.

X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment. The company is developing two unique programs such as drug candidate, X4P-001, has clinical experience in over 70 subjects, and is advancing into Phase 1/2 trials in refractory clear cell renal cell carcinoma (ccRCC) and refractory epithelial ovarian cancer (EOC), the second program, X4P-002, is a unique series of late lead molecules that penetrate the blood-brain barrier. They will pursue early clinical development in glioblastoma multiforme (GBM), a rare form of lethal brain cancer, for the X4P-002 program. X4 Pharmaceuticals was founded in 2014 and is based in Cambridge, Massachusetts, United States.

LogicBio develops gene therapy vectors for previously incurable genetic and infectious diseases, including: hemophilia, HIV/AIDS and methylmalonic acidemia (MMA). Our proprietary technology based on the non-pathogenic Adeno-Associated Viral (AAV) vector offers superior efficiency and safety compared to all competitors on the market, and is uniquely suited for the treatment of children as well as adults.

ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The Company's technology enables targeting loss-of-gene features of solid tumor cells, sparing normal, healthy tissues.

Zentera Therapeutics is a biopharmaceutical company.

Adela is focused on the detection of cancer and other high-morbidity, high-mortality conditions through a routine blood test.

Scout Bio, Inc. researches and develops one-time therapies for major chronic pet health conditions using veterinary biotechnology and gene therapy. It offers therapies for anemia associated with chronic kidney disease (CKD) in cats. The company offers pet therapeutics, including small molecular drugs, protein therapies, and gene therapies. Scout Bio, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Rimag provides medical imaging service. The company engages in medical imaging center operation, relevant cloud technology development, and talent training. The company was founded in 2014 and is based in Shenzhen, China.

Laekna Therapeutics Shanghai Co., Ltd. is a gene therapy company, which develops therapeutics for oncology and metabolic diseases. It develops pre-clinical discovery programs for oncology and liver diseases. It develops small molecule candidate LAE001 (previously known as CFG920) for prostate cancer. The company was founded in 2016 and is based in Shanghai, China.

Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Therachon is headquartered in Basel, Switzerland, with research labs in Nice, France.

Cleave Therapeutics develops oncology pharmaceuticals designed to target neurodengeneration and pathways used by cancer cells to grow. The company is engaged in the discovery of novel, small-molecule drugs that affect protein-degradation pathways, upon which cancer cells depend for survival, enabling patients to get cured from cancer.

Pandion Therapeutics is a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation at the site of disease for durable, tissue-specific treatment of patients with autoimmune and inflammatory diseases, and organ transplants. Pandion’s approach has the potential to more effectively induce and sustain response and remission in patients with many autoimmune and inflammatory conditions. They aim to shift the paradigm and create a new generation of drugs with transformative efficacy and improved safety.

Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and improve the quality of human life. The product development portfolio of the Company includes MultiStem, a stem cell product, which is being developed as a treatment for multiple disease indications, and is being evaluated in two ongoing clinical trials, and has been authorized for use in a third clinical trial. In addition, the Company is developing pharmaceuticals to treat indications such as obesity, certain cognitive and attention disorders, and narcolepsy or other forms of excessive daytime sleepiness.

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company’s second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.

Mereo BioPharma Group plc, a specialty biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of rare and specialty diseases. Its product candidates include BPS-804, a monoclonal antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfecta; AZD-9668, an oral small molecule that has been completed Phase I clinical trial to treat Alpha-1 antitrypsin deficiency; BGS-649, an oral aromatase inhibitor, which is in Phase IIb clinical trial for the treatment of hypogonadal hypogonadism; and BCT-197, an oral p38 MAP kinase inhibitor that is in Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease. Mereo BioPharma Group plc was founded in 2015 and is headquartered in London, the United Kingdom.

Caris Molecular Intelligence revolutionizes precision medicine to provide physicians and patients with information about their health. They develop Caris Molecular Intelligence Services that does panomic molecular profiling for oncology. Caris Life Sciences was founded with a very simple but powerful purpose – to help improve the lives of as many people as possible. Through tireless efforts, breakthrough molecular science, and a passionate commitment to quality, they remain steadfastly focused on the most important part of their work – the patient. It was founded in 1996 and is based in Irving, Texas.

resTORbio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases.The Company develops medicines and therapies to treat aging-related diseases and conditions such as cancer, heart disease, neurodegenerative diseases, and diabetes mellitus. resTORbio serves clients in the State of Massachusetts.

Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief. Q32 Bio consists of a team of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies.

Verona Pharma is a biotechnology company dedicated to discovering new drugs for the treatment of chronic respiratory diseases, such as asthma, allergic rhinitis (hay fever), chronic obstructive pulmonary disease (COPD) and cough.

Noctrix Health, Inc. develops therapeutic wearable devices to treat chronic neurological and sleep disorders in patients. The company was founded in 2018 and is based in Menlo Park, California.

Principia Biopharma is a private, pre-clinical stage company initially focused on the discovery and development of differentiated small molecule drugs targeting inflammatory/autoimmune diseases as well as cancer. The company expects to submit an IND for its lead program in 2013 and continues to invest in additional programs and its reversible covalent platform.

Salmedix is an oncology drug development company with a commercial focus on the treatment of hematologic malignancies, or blood cancers. Its primary product, SDX-105, is marketed by healthcare professionals in Germany for the treatment of several types of blood cancers. Salmedix conducts Phase II clinical trials for SDX-105 in the U.S. and Canada. Its other clinical-stage product candidates, SDX-101 and SDX-102, each with significant prior human clinical experience, are also in Phase II development. Founded in 2000 by David Kabakoff, Salmedix is headquartered in San Diego, California.

Modis Therapeutics, Inc. develops disease modifying therapies for rare genetic diseases. The company designs and develops a therapy MT1621, which restores mitochondrial DNA replication fidelity. The company was incorporated in 2016 and is based in Oakland, California. As of September 6, 2019, Modis Therapeutics, Inc. operates as a subsidiary of Zogenix, Inc..

Compass Therapeutics is a clinical-stage biotechnology company targeting the human immune synapse with a new generation of antibody therapeutics. Compass has broadly drugged the immune system by generating epitopically diverse antibody panels to more than 40 targets across all immune cell types and is leveraging its proprietary StitchMabs and common light-chain based multispecific platforms to empirically identify combinations and multispecific with optimized activity. The company’s lead product candidate, CTX-471, is a fully human agonistic antibody of CD137, which is in a Phase 1 study in patients with inadequate responses to PD-1/PD-L1 checkpoint inhibitors. Compass is also progressing several preclinical assets including a novel class of NK cell engagers targeting NKp30 and multiple bispecific checkpoint programs. The company’s offices and labs are based in Kendall Square in Cambridge, Mass.

ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts. It discovers and develops innovative therapeutics that can utilize a family of endogenous enzymes called adenosine deaminase acting on RNA (ADAR) to precise target and correct single point mutations on an mRNA, thus the production of desired and functional protein is restored. It was founded in 2019 and is headquartered in San Diego, California.

Relypsa, Inc. is a privately-held, development stage biopharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal disease. Relypsa's lead product candidate is RLY5016, a non-absorbed potassium binder for the management of hyperkalemia. Relypsa is dedicated to discover additional product candidates through use of its proprietary polymer platform.

NeurAxon, Inc. discovers and develops pain therapeutics targeting neuronal nitric oxide synthase. It has oral products in pipeline addressing acute migraine, neuropathic pain chronic daily headache, inflammatory pain, migraine prophylaxis, and severe pain. The company was founded in 2004 and is headquartered in Toronto, Canada.

Adagio Therapeutics, Inc., a biotechnology company, develops antibodies that neutralize SARS-CoV-2, SARS-CoV-1, and potentially emergent coronaviruses. Its portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

MiroBio Ltd develops and manufactures antibody modulators of immune cell receptors for auto-immune diseases. The company is developing antibodies and variants to stimulate specific immune cell signals to harness the natural control mechanisms of the immune system. The company was incorporated in 2018 and is headquartered in Oxford, United Kingdom.

Janux Therapeutics develops immunotherapies that generate immune responses to prevent tumors and not affecting a patient’s healthy tissue. Janux technology targets all three stages of the anti-tumor immune response. Janux Therapeutics, Inc. was founded in 2017 by David Campbell and is based in La Jolla, California.

Foamix Pharmaceuticals Inc. a pharmaceutical company, engages in development and commercialization of proprietary, innovative, and differentiated topical drugs for dermatological conditions. It offers Molecule Stabilizing Technology (MST) platform. The company was incorporated in 2014 and is based in Bridgewater, New Jersey. Foamix Pharmaceuticals Inc. operates as a subsidiary of Menlo Therapeutics Inc.

Nuohui Health is an innovative bio-tech company focusing on early screening and genetic testing services for high-incidence cancer homes. Nuohui Health is committed to reducing the morbidity and mortality of cancer through biotechnological means. It first proposed the slogan of early cancer screening and is committed to promoting early cancer screening into thousands of households so that the public can enjoy convenient and efficient health services .

Gemini Therapeutics is a precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases.Their therapeutic candidates are matched to molecular abnormalities found in patients with high clinical need and our broad multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. Launched with funding from leading life science investors and powered by academic partnerships around the world,they are developing a series of potentially first-in-class therapeutics.

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.

Founded in March 2015, EUSA Pharma is a newly-established, profitable specialty pharmaceutical company with global reach from its headquarters in the UK and its commercial operations across Europe and the USA. Currently, EUSA Pharma has a portfolio of five approved as well as several named-patient specialty hospital products, including: Caphosol®, Xenazine®, Collatamp®, Custodiol® and Fomepizole® EUSA submitted the MAA for FOTIVDA (tivozanib HCL) as first line therapy for RCC in Q1 of 2016. EUSA Pharma has ambitious plans to expand its portfolio through acquisition and in-licensing and is led by an experienced management team with a strong record of building successful specialty pharmaceutical companies. The EUSA Pharma business is supported by significant funding raised from leading life science investor Essex Woodlands. In addition to direct commercial operations across the EU and US, EUSA Pharma also has a wide distribution network of commercial partners in Europe, the Middle East, Asia and Latin America and makes products available in approximately 40 countries across the world through this broad international platform.

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.

Valneva is a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs. The Company has a growing commercial business with two successful vaccines for travelers and multiple vaccines in development. This includes the only developmental stage vaccine candidate to prevent Lyme disease, a tick-transmitted illness with a growing global footprint.

Adimab's integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and expressability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.

Sparrow Pharmaceuticals develops therapies for conditions of corticosteroid excess. The company was founded in 2013 by David A. Katz and is based in Portland, Oregon, United States.

Audentes Therapeutics is a biotechnology company committed to the development and commercialization of innovative new gene therapy treatments for people with serious rare diseases. We are a focused, experienced and passionate team driven by the goal of improving the lives of patients.

Neurogastrx, Inc. manufactures biopharmaceutical products for the treatment of gastrointestinal disorders. The company develops product such as NG101 that increases gastric motility and contains antiemetic properties. Neurogastrx, Inc. was incorporated in 2017 and is based in Campbell, California.

Janux Therapeutics develops immunotherapies that generate immune responses to prevent tumors and not affecting a patient’s healthy tissue. Janux technology targets all three stages of the anti-tumor immune response. Janux Therapeutics, Inc. was founded in 2017 by David Campbell and is based in La Jolla, California.

Azura Ophthalmics is a clinical-stage company that develops an innovative portfolio of compounds to advance treatments for MGD, the leading cause of DED. By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatment options are currently lacking. Azura is underpinned by an experienced management team with an established track record of successfully developing and commercializing novel treatments for ocular surface diseases. The company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the U.S.

Xtant Medical, a medical company, manufactures, markets, and develops regenerative medicine products and medical devices for international and domestic markets. Bacterin International and X-spine Systems have combined to form XTANT Medical (NYSE MKT: XTNT), a comprehensive supplier of orthopedic and spine surgery products. Pairing the orthobiologics line-up of Bacterin with the hardware suite of X-spine, the union creates an extensive portfolio of complementary products that serve the needs of the orthopedic and neurosurgery markets, with minimal overlap. The combined company has an expanded national footprint of over 300 field sales representatives and more than 50 national accounts and regional health systems/IDN contracts, positioning XTANT Medical as a strong competitor in the spine surgery marketplace. With both Bacterin and X-spine operating units healthy and thriving, the resulting synergy increases the potential for accelerated growth and market penetration. Xtant Medical was founded in 2015 and is headquartered in Montana, USA.

Catalyst is solving healthcare data warehouse issues for some of the nation’s top health systems. With the shift from paper to electronic records, it has become a challenge to organize health data, make sense of it, and to do it quickly. Catalyst helps organize, normalize, and link the data from all different systems. And they make it searchable by all users, even the non-technical, by using rich metadata capabilities.

SpringWorks Therapeutics is a biotechnology company that specializes in identifying, developing, and commercializing therapies for underserved patient populations suffering from severe rare diseases and cancer. The firm's pipeline product includes Mirdametinib, Nirogacestat, and others. The company was founded in 2017 and headquartered in Connecticut, United States.

BiomX discovers and develops innovative microbiome therapeutics. The Company's mission is to develop novel therapeutics for preventing and treating diseases in which microbiome imbalances have been implicated. BiomX's microbiome modulation technologies are based on the cutting-edge innovative research of its scientific collaborators: Professor Rotem Sorek, PhD and Dr. Eran Elinav, MD, PhD both of the Weizmann Institute of Science and Professor Timothy K. Lu, MD, PhD of the Massachusetts Institute of Technology.

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. The company also develops next-generation transgenic mice that provide a source of fully-human antibodies for the discovery of therapeutic antibody candidates. It has a discovery partnership agreement with Eli Lilly and Company for the discovery of various targets. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada.

Passage Bio, Inc., a genetic medicines company, focuses on developing transformative therapies for rare monogenic central nervous system (CNS) diseases. It has research, collaboration, and license agreement with the University of Pennsylvania and its gene therapy program; and The Trustees of the University of Pennsylvania for research and development collaborations, and exclusive license rights to patents for certain products and technologies. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.

Acutus Medical develops medical technologies to treat complex cardiac arrhythmia. The company's platform displays the heart’s true activation pattern, turning the chaos of a complex arrhythmia into a clear vision for electrophysiologists. Acutus Medical is a privately funded company founded in 2011 and based in Carlsbad, California. Its products are co-developed in the U.S. and Europe with an exceptional team of medical scientists, biomedical engineers, and other professionals. It was founded in 2011 and headquartered in Carlsbad, California.

ArriVent is dedicated to accelerating the global development of innovative biopharmaceutical products.

Edge Medical Robotics, Inc. was founded in Longgang, Shenzhen, China on May 4, 2017. It is committed to researching and promoting most advanced smart equipment in the world，polishing the ultimate product with the spirit of pursuing excellence and fineness, improving surgical safety and treatment efficacy, and contributing to uprising the level of social health.

Tricida, Inc. is a late-stage pharmaceutical company focused on the development and commercialization of its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. Metabolic acidosis has been associated with increased muscle wasting, loss of bone density and death.

PMV Pharma is developing first-in-class p53 and p53 pathway modulators for the treatment of cancer. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.

Clementia is a clinical-stage company innovating treatments for people with ultra-rare bone disorders. The company develops disease-modifying treatments for patients suffering from debilitating bone and other diseases with a high unmet medical need. The company's lead product candidate, palovarotene, is an oral small molecule that has shown potent activity in preventing abnormal new bone formation as well as fibrosis in a variety of tissues. Clementia Pharmaceuticals was founded in 2012 and is headquartered in Montréal, Quebec.

GrayBug is a pharmaceutical company that focuses on developing the next generation of products for the treatment of chronic vision-threatening diseases of the retina and optic nerve. The company is currently developing a continuum of proprietary micro – and nanoparticle controlled release technologies and implants for strategic partnership and its own therapeutic products for major ocular disease indications including wet AMD and Glaucoma. The company was founded in 2011 and headquartered in Baltimore, Maryland.

MabPlex International Ltd provides contract development and manufacturing of biopharmaceuticals including, monoclonal antibodies (mAbs), recombinant proteins, Antibody Drug Conjugates (ADCs) and bispecifics. It offers customized mammalian cell medium, cell banking, monoclonal antibodiy active pharmaceutical ingredient (API) manufacturing, and biologics and ADC fill and finish manufacturing. The company was founded in 2013 and is based in Yantai, China with an additional office in Fremont, California.

MID Labs was founded by Dr. Carl Wang in 1981 and has been associated with vitreoretinal surgery from its infancy. Not only has MID Labs invented the tools for modern vitrectomy, but as a company, it has been instrumental in revolutionizing the ophthalmic field through its products. MID Labs continues to innovate with the MID Labs branded product line which is supplied to more than 30 countries around the world. These products set the standard for precision, performance, and quality.

A bio­pharmaceuti­cal company focused on the devel­opment and com­mer­cializa­tion of antibi­otics

ARIUS Research, Inc., a biotechnology company, engages in the discovery and development of antibody therapeutics primarily focusing on breast, prostate, ovarian, colorectal, pancreatic and lung cancers, leukemia, and melanoma. It identifies monoclonal antibodies targeting various cancer indications through its technology platform, FunctionFIRST. The company's product pipeline includes CD63 program that is in preclinical studies for various cancer indications; ARH460-16-2, an antibody targeting the cancer stem cell antigen CD44; AR36A36.11.1 and AR10A304.7, which targets the complement-inhibitory molecule CD59; AR47A6.4.2 and AR52A301.5, which are monoclonal antibodies directed to the cancer-associated protein TROP-2 that is homologous to human EpCAM, an another cell surface cancer related protein; and AR40A746.2.3 that targets leukemia cancer stem cells. It also has antibody programs targeting the MCSP antigen and 37LRP. ARIUS has partnerships with Oxford BioMedica plc, Xerion Pharmaceuticals AG, PDL BioPharma, Inc., Medarex, Inc., Genentech, Inc., and Takeda Pharmaceutical Company Limited. The company was founded in 1999 and is based in Toronto, Canada. As of September 23, 2008, Arius Research Inc. operates as a subsidiary of Roche Holding AG.

DarioHealth Corp is a digital health company. It is engaged in the development and commercialization of patented and proprietary technology that provides consumers with laboratory-testing capabilities using smartphones and other mobile devices. The company's product, Dario Blood sugar monitor is a mobile, real-time, cloud-based, diabetes management solution based on a multi-featured software application combined with a blood glucose monitoring device. The group operates internationally and derives revenues from the sale of its Dario smart meter and related device-specific disposables test strip cartridges and lancets. The company generates the majority of the revenue.

Uquifa is a manufacturer of Active Pharmaceutical Ingredients (APIs) and intermediates for the pharmaceutical Industry. Operates 3 manufacturing sites, 2 in Spain and 1 in Mexico, which operates under cGMP conditions and has been inspected and approved by major Pharmaceutical Companies and Regulatory Authorities, including the US FDA.

SAGE Therapeutics is dedicated to the health and well being of patients with central nervous system (CNS) disorders. Their mission is to discover, develop and deliver novel medicines for many of today's most debilitating and disabling CNS disorders by leveraging compelling science, a robust clinical foundation, strong partnerships, and a world-class team of founders, advisors, investors, scientists and managers.

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. It also is developing OBE022, an oral and selective prostaglandin F2α, or PGF2α receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company was founded in 2012 and is headquartered in Geneva, Switzerland.

Nutrinia is a neonatology company developing pharmaceuticals to treat rare conditions of the gastrointestinal tract. Our current products in development are oral formulations of insulin shown to enhance adaptation and rehabilitation of the gut in infants. We at Nutrinia live by the belief that science is best used to make life better for people, especially the most vulnerable populations.

PierianDx is catalyzing global adoption of genomic sequencing in healthcare by empowering physicians in the laboratory and clinic to more effectively diagnose and treat patients with cancer and other complex diseases. PierianDx’s industry-leading genomic SaaS solutions, CAP and CLIA accredited laboratory, and shared knowledgebase are used by health systems, cancer centers and commercial laboratories worldwide driving the most integrated approach across the clinical care spectrum. From genomic sequencing and biomedical informatics in the laboratory to reporting and decision support at the patient’s bedside, PierianDx has rapidly become the trusted source of ‘wisdom’ in every advanced genomic report.

Zentera Therapeutics is a biopharmaceutical company.

MDClone Ltd. designs and develops software that analyzes medical records. Its software platform creates synthetic medical records for fictitious patients, avoiding the risk of public disclosure of actual medical data. The company’s platform enables researchers to examine the behavior of the disease, doctors, drugs, and health organizations without risking private patient medical data. MDClone Ltd. was founded in 2016 and is based in Beersheba, Israel.

ViewRay, Inc. designs, manufactures, and markets radiation therapy systems. The company offers MRIdian, a magnetic resonance image guided radiation therapy system to image and treat cancer patients. Its MRIdian integrates MRI technology, radiation delivery, and proprietary software to see the soft tissues, shape the dose to accommodate for changes in anatomy, and strike the target using real-time targeting throughout the treatment. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. markets its MRIdian through a direct sales force and distribution network. It has operations in the United States, France, Germany, and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

GeneFormatics is a biotechnology company specializing in structural proteomics.

Agensys a biotechnology company, engages in the research and development of therapeutic human monoclonal antibodies and antibody drug conjugates for the treatment of cancer. It offers products to treat various tumors, as well as prostate, pancreatic, and bladder cancers. The company, formerly known as UroGenesys, was founded in 1997 and is based in Santa Monica, California. As of December 18, 2007, Agensys, Inc. operates as a subsidiary of Astellas Pharma US, Inc.

Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology. GMAB is an adaptive technology that uses a novel, cell-penetrating antibody to non-covalently bind to and deliver therapeutic levels of a wide variety of nucleic acid payloads to select cells. This non-viral delivery platform is differentiated from traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and employs well-established manufacturing processes. Gennao Bio is developing this delivery system with an initial focus on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases.

Kala Pharmaceuticals is developing novel treatments for diseases that affect mucosal tissues. The company's proprietary mucus penetrating particle technology dramatically improves drug distribution and pharmacokinetics by uniformly coating the mucosal surface with biocompatible, drug-loaded particles. Kala's formulations achieve high, sustained local drug concentrations with reduced systemic exposure and are delivered in a patient friendly format. The company's research efforts have demonstrated successful in vivo proof-of-concept in mucosal organs such as the respiratory tract, eye, and cervicovaginal tract, enabling diverse product opportunities that target significant clinical unmet need. Kala is focused on advancing an internal pipeline of products through human proof-of-concept, while establishing R&D collaborations with select partners to improve products in their pipelines.

Tricida, Inc. is a late-stage pharmaceutical company focused on the development and commercialization of its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. Metabolic acidosis has been associated with increased muscle wasting, loss of bone density and death.

MacroGenics, Inc., a biotechnology company, focuses on the development, manufacture, and commercialization of immunotherapeutics for autoimmune disorders, cancer, and infectious diseases. The company is developing immune-based products, including monoclonal antibodies; and vaccines to prevent infections in healthy individuals. The company's Fc engineering technology enables to improve antibody functions to eliminate cancer cells. It is also developing products around the Dual Activating ReTargeting technology. The company was founded in 2000 and is headquartered in Rockville, Maryland.

Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science which is focused on selective regulators of epigenetic function, which are critical to controlling gene expression.

Magenta is focused on improving the patient experience in transplant medicine, with the goal of bringing this lifesaving procedure to more patients. Over the past 50 years, stem cell transplantation has been used in more than 1M patients worldwide. It is currently the only treatment with the potential to cure some of the most devastating hematologic cancers and autoimmune diseases. Despite the increased use and clinical advancements over the past several decades, stem cell transplant remains a high-risk last-resort therapeutic option due to the toxicity and potential long-term side effects.

Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that pointedly address long-standing unmet needs in oncology. Guardant is backed by Sequoia Capital, led by a seasoned management team comprising thought leaders and successful serial entrepreneurs in next-generation sequencing and rare-cell diagnostics and is closely advised by an oncologist-led medical steering committee from leading cancer centers across North America and abroad.

Principia Biopharma is a private, pre-clinical stage company initially focused on the discovery and development of differentiated small molecule drugs targeting inflammatory/autoimmune diseases as well as cancer. The company expects to submit an IND for its lead program in 2013 and continues to invest in additional programs and its reversible covalent platform.

Aerin Medical Inc. develops non-invasive treatment solutions to improve nasal breathing disorders. It offers VivAer procedure for treating nasal obstruction; and RhinAer procedure for chronic rhinitis. The company also provides VivAer Stylus for nasal airway obstruction; and RhinAer Stylus for chronic rhinitis. The company was incorporated in 2011 and is based in Sunnyvale, California.

GC-Rise Pharmaceutical Co., Ltd. is a solely-foreign-owned enterprise invested by INVENTAGES, a famous European investment group engaged in healthcare industry. Taking “Devoted to human healthcare and a better life” as our mission, the company makes full use of the business networks of our strategic cooperation partner in America, Europe and Japan, their affluent experiences in clinical development, clinical trials and registration in China, and their abundant strength in commercial distribution, hospital sale, marketing, so as to provide novel, safe, and highly efficient medical products and treatment ideas for Chinese patients.

TytoCare Ltd. develops handheld devices and application that connects people with doctor for an on-demand medical exam, diagnosis, and prescription if needed, anytime, and anywhere. The company’s tools help in examining the heart, lungs, skin, ears, throat, abdomen, and body temperature, and diagnose and treat various common conditions, such as ear infections, cold and flu, fever, headaches, eye irritation, congestion, sinus pain, allergies, sore throat, coughs and upper respiratory issues, bug bites and rashes, constipation, and stomachaches. TytoCare Ltd. has a strategic partnership with Novant Health. The company was incorporated in 2011 and is based in Netanya, Israel with an additional office in New York, New York.

Miaoshou Doctor is a healthcare service platform for building an online communication service platform between patients and doctors. It helps healthcare professionals and patients to manage post-diagnosis outcomes and allows doctors to actively follow up with their patient's health through additional counseling and prescriptions. Tao He and Daoliang Han founded the company in 2015 and is based in Beijing, Beijing.

Response Biomedical Corp. ("Response") (TSX: RBM, OTCBB: RPBIF) develops, manufactures and markets rapid on-site diagnostic tests at its world class manufacturing facility in Vancouver, Canada, for use on the RAMP® Platform. The RAMP® Platform is sold worldwide and includes a variety of testing applications in the clinical, infectious disease, biodefense and environmental arenas. The RAMP® Platform provides laboratory quality results with the speed, precision and accuracy that many hospitals expect of their central lab systems. It is ideally suited for both point of care testing and laboratory use.

Realm Therapeutics is a biopharmaceutical company passionately committed to leveraging its proprietary technologies to protect and improve the health of adults and children. The Company's drug development focus, utilizing its immunomodulatory formulations, is targeted initially on developing small molecule therapies in inflammatory diseases with potential application in dermatology and ophthalmology, and the potential for broad applicability across a number of other diseases.

Aspen Neuroscience, Inc. develops induced pluripotent stem cells to treat neurological conditions. Its products pipeline includes ANPD001, an autologous neuron replacement therapy in sporadic Parkinson disease; and ANPD002, a gene-edited autologous neuron replacement therapy for familial forms of Parkinson disease. The company was incorporated in 2018 and is based in San Diego, California.

To this end, arGEN-X has invented and developed a breakthrough discovery platform setting the new standard for antibody lead choice in the discovery of human antibody therapeutics. Fuelled by the best possible natural immune responses available, our Simple Antibodyâ„¢ platform leapfrogs existing platforms in what is probably the most critical aspect of drug discovery and development: lead choice.

RemeGen, Ltd. ("RemeGen") is a biopharmaceutical company in China dedicated to fulfilling unmet medical needs for patients with life-threatening conditions. RemeGen's main focus is research and development, manufacturing and commercialization of novel biologics, most notably monoclonal antibodies (mAb) and antibody-drug conjugates (ADCs). Headquartered in Yantai, Shandong Province, China, RemeGen has labs/offices in Beijing and California.

XtalPi is a biotech firm that uses artificial intelligence and computing to accelerate the development of new drugs. The firm uses algorithms to predict the crystalized form a drug will take. The data enables XtalPi to work with other pharmaceutical companies to develop new drugs and create new patents. It was founded in 2014 and headquartered in Cambridge, Massachusetts.

NeRRe Therapeutics Ltd. develops preclinical and clinical neurokinin (NK) receptor antagonists. The company focuses on NK-1 antagonist asset orvepitant as an oral treatment for intense pruritus induced by targeted anti-cancer therapies. It offers NT-814, a NK-1, 3 antagonist; NT-949, a Phase I ready NK-1 antagonist; and NT-432, a NK-1 antagonist clinical candidate. The company was founded in 2012 and is based in Stevenage, United Kingdom.

Perfuse Therapeutics specializes in developing therapies for the treatment of eye disease. The company is pursuing a novel mechanism to treat various eye diseases, starting with glaucoma, by improving retinal perfusion.

ChemomAb is a clinical stage biopharmaceutical company, founded in 2011. ChemomAb specializes in the development of proprietary monoclonal antibodies, directed towards novel targets, for the treatment of immune-mediated and fibrotic disorders including orphan indications. The leading compound, CM-101, was selected after meticulous testing in a series of pre-clinical animal models simulating human disorders and has shown promising safety and efficacy as well as a novel mechanism of action.

NeoGenesis Pharmaceuticals, Inc. is a drug discovery company which uses it proprietary affinity-based screening technologies and integrated chemical library and chemistry approaches to discover and develop a portfolio of small molecule drugs, both for itself and for its collaboration partners. The company's widely applicable and unbiased affinity-based technologies, coupled with its proprietary library of diverse drug-like compounds, provide efficiency in lead discovery and optimization, NeoGenesis' core technology, the Automated Ligand Identification System (ALIS), is a rapid, affinity-based system for identifying and optimizing novel drug leads that in many cases may not have been identified with traditional screening approaches. Coupled with the company's NeoMorph compound library, ALIS enables the identification and optimization of novel and selective drug leads against validated and emerging new targets. The company was founded in 1997 and is headquartered in Cambridge, Massachusetts.

DFINE Inc. develops minimally invasive therapeutic devices that are used to treat pathologies of the vertebrae, metastatic spinal tumors, and vertebral compression fractures. It offers STAR, a tumor ablation system for palliative treatment in spinal procedures by ablation of metastatic malignant lesions in a vertebral body; vertebral augmentation systems for percutaneous delivery of bone cement and the treatment of pathological fractures; and vertebroplasty systems. The company was founded in 2004 and is based in San Jose, California. As of July 6, 2016, DFINE Inc. operates as a subsidiary of Merit Medical Systems, Inc..

Delfi Diagnostics detect cancer early, when it is most curable, using high precision non-invasive blood tests. It uses artificial intelligence and genome sequencing to detect unique patterns of DNA fragmentation in the blood of patients. It was founded in 2019 and is headquartered in Baltimore, Maryland.

Corus Pharma is a biotech and specialty drug company that focuses on respiratory and infectious diseases. In other words, it is a development stage biopharmaceutical company that focuses on the development and commercialization of novel applications and formulations of known therapeutics to treat severe respiratory diseases. The products of the company are Corus 1020 and 1030. Corus 1020 is designed to treat respiratory infections in cystic fibrosis patients, using an inhalable form of an antibiotic called aztreonam. Corus 1030 is inhaled lidocaine for the treatment of patients suffering from the severe persistent forms of asthma. Corus Pharma is a U.S.-based company that was founded in 2001 and the company was acquired by Gilead Sciences on October 22, 2006.

Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. The company also develops a novel, a closed-loop solution that continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. Inspire Medical Systems, Inc. was founded in 2007 and is headquartered in Golden Valley, Minnesota.

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering and developing small molecule drugs and therapeutics for the treatment of chronic fibrotic and metabolic diseases. It offers INT-747, a FXR modulating agent that treats patients with chronic autoimmune liver diseases. The company's drug development programs also focus on modulating bile acid receptors, and amelioration of metabolic and hepatic functions in chronic liver diseases. Intercept Pharmaceuticals, Inc. was founded in 2002 and is based in New York, New York.

ARYx is a product-driven pharmaceutical company with leading expertise and significant intellectual property in the area of retrometabolic drug design. They are focused on improving the safety of oral therapies for chronic disease.

SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. SI-BONE, Inc. was founded in 2008 and is headquartered in Santa Clara, California.

Clementia is a clinical-stage company innovating treatments for people with ultra-rare bone disorders. The company develops disease-modifying treatments for patients suffering from debilitating bone and other diseases with a high unmet medical need. The company's lead product candidate, palovarotene, is an oral small molecule that has shown potent activity in preventing abnormal new bone formation as well as fibrosis in a variety of tissues. Clementia Pharmaceuticals was founded in 2012 and is headquartered in Montréal, Quebec.

Foamix Pharmaceuticals Inc. a pharmaceutical company, engages in development and commercialization of proprietary, innovative, and differentiated topical drugs for dermatological conditions. It offers Molecule Stabilizing Technology (MST) platform. The company was incorporated in 2014 and is based in Bridgewater, New Jersey. Foamix Pharmaceuticals Inc. operates as a subsidiary of Menlo Therapeutics Inc.

Targanta Therapeutics a biopharmaceutical company focused on the development and commercialization of innovative antibiotics for serious infections treated or acquired in hospitals and other institutional settings.

Receptos is a privately-held drug discovery and development company which utilizes pioneering G protein-coupled receptor (GPCR) technology to facilitate information-driven drug design for developing best- and first-in-class drugs.

Insilico Medicine, an artificial intelligence company headquartered in Rockville, MD, pioneered the applications of the generative adversarial networks (GANs), reinforcement learning, transfer learning and meta-learning for generation of novel molecular structures for the diseases with known and unknown targets, and, unlike the other companies in the field, is developing the end-to-end pipeline covering every step of drug discovery, clinical trials analysis and digital medicine. Insilico Medicine is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with Life Extension, the company launched a range of nutraceutical products, which were compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. The company also develops next-generation transgenic mice that provide a source of fully-human antibodies for the discovery of therapeutic antibody candidates. It has a discovery partnership agreement with Eli Lilly and Company for the discovery of various targets. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada.

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead program is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of metastatic or locally advanced, ER-positive, and human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Theseus Pharmaceuticals is a Technology based company.

Azura Ophthalmics is a clinical-stage company that develops an innovative portfolio of compounds to advance treatments for MGD, the leading cause of DED. By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatment options are currently lacking. Azura is underpinned by an experienced management team with an established track record of successfully developing and commercializing novel treatments for ocular surface diseases. The company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the U.S.

Zylox Medical Device Co. was founded in the beautiful city of Hangzhou in 2012 by a group of highly skillful and experienced returnees from the US and Europe. They have on average 5-20 years of working experiences in various functional areas such as research and development, management, and manufacturing in leading device makers including Johnson & Johnson, Medtronic, and Abbott before returning to China. Since its inception, Zylox has developed an increasingly rich product pipeline of interventional and implantable peripheral vascular devices such as PTA balloons, PTA drug-coated Balloons (PTA DCB), superficial femoral artery (SFA) stent, drug-eluting SFA stent, and other vascular accessories. Zylox strives to continuously innovate and provide patients with superior quality medical devices.

Ruipeng Pet Hospital is a Shenzhen-based pet medical and beauty care hospital operator, which covers pet healthcare, foster care, bathing, SPA, beauty, food, entertainment and leisure services.

MobileODT builds small, smart, connected visual diagnostic tools to enable any health provider, anywhere, to conduct examinations on the level of an expert practitioner. Empowering less-trained providers increases the reach of health systems, reducing costs, and improving outcomes. The Enhanced Visual Assessment (EVA) System is our first product, an FDA cleared internet-connected mobile colposcope and is growing rapidly in market share in the US, across Africa, and India. It is used in the world’s harshest environments and receives accolades from clinicians in the world’s leading hospitals (MD Anderson, Mount Sinai, Apollo). EVA has been used for over 40,000 procedures in 29 countries. Our customers include the world’s leading hospital groups West and East, and our fastest-growing market is the US, where we are becoming the standard for visualization (+20% of hospitals in New York State who offer Sexual Assault Forensic Examinations use EVA). We are growing rapidly in new geographies and have in the pipeline additional visual-based applications, including ENT, Oral disease, and Skin.

ForteBio is a venture-capital funded life science company developing analytical systems to provide rapid, real-time results for protein quantification or characterization of protein-protein interaction. These systems enable real-time analysis of biomolecular interactions in micro-volume sample sizes, providing information on affinity, kinetics, and concentration.

Relypsa, Inc. is a privately-held, development stage biopharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal disease. Relypsa's lead product candidate is RLY5016, a non-absorbed potassium binder for the management of hyperkalemia. Relypsa is dedicated to discover additional product candidates through use of its proprietary polymer platform.

Theseus Pharmaceuticals is a Technology based company.

Puma Biotechnology, Inc., is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The Company is initially focused on the development of PB-272 (oral neratinib), a potent irreversible tyrosine kinase inhibitor, for the treatment of patients with HER2 positive metastatic breast cancer.

Kinnate Biopharma develops precision oncology therapeutics to treat patients with genomically-defined cancers. Its mission is to expand the reach of targeted therapeutics by developing products for underserved populations. The company utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine. Its programs include candidates in preclinical development for cancers that are driven by specific oncogenic alterations in either the BRAF kinase gene or in the FGFR2 and FGFR3 kinase genes.

Rempex Pharmaceuticals, Inc. is a San Diego-based pharmaceutical company focused on the discovery and development of new antibacterial drugs to meet the growing clinical need created by multi-drug resistant bacterial pathogens. The company’s internal development pipeline focuses on combining proprietary formulations, PK/PD strategies and novel potentiating agents with proven antibiotics to overcome or directly inhibit the molecular mechanisms in bacteria responsible for antibiotic resistance.

Adicet Bio is a pre-clinical stage biotechnology company engaged in the design and development of cutting-edge allogeneic immunotherapies for cancer and other diseases.

Silverback Therapeutics is a biopharmaceutical company that develops ImmunoTAC therapies targeting previously inaccessible disease pathways. They developing a new generation of systemically delivered, locally active therapies that potently modulate fundamental disease pathways once deemed inaccessible. Silverback Therapeutics is building a platform technology capable of unlocking potent immuno-modulatory pathways using an established antibody-guided approach for targeting disease sites. The company's proprietary ImmunoTAC technology and integrated R&D approach enables the design of product candidates that can be administered systemically, but that act only at the sites of disease.

TytoCare Ltd. develops handheld devices and application that connects people with doctor for an on-demand medical exam, diagnosis, and prescription if needed, anytime, and anywhere. The company’s tools help in examining the heart, lungs, skin, ears, throat, abdomen, and body temperature, and diagnose and treat various common conditions, such as ear infections, cold and flu, fever, headaches, eye irritation, congestion, sinus pain, allergies, sore throat, coughs and upper respiratory issues, bug bites and rashes, constipation, and stomachaches. TytoCare Ltd. has a strategic partnership with Novant Health. The company was incorporated in 2011 and is based in Netanya, Israel with an additional office in New York, New York.

Innovative Spinal Technologies is a spine technology company that develops motion preservation and minimally invasive treatments for spinal disorders. Its products include AXIENT Dynamic Fixation system, a pedicle screw-based motion system, PARAMOUNT Lumbar Fusion System, which is engineered for lumbar fusion procedures conducted in a minimally invasive, mini-open, or open fashion, PARAMOUNT MIS Pedicle Screw System for single and multi-level procedures, PARAMOUNT Open Pedicle Screw System, which is designed to meet the needs of minimally invasive lumbar fusion, and PARAMOUNT VBR, which is designed for a minimally invasive transforaminal approach. Innovative Spinal Technologies was founded in 2002 and is headquartered in Mansfield, Massachusetts

Sientra, Inc., a medical device company, develops and markets products focusing on the plastic surgery and aesthetics market. The company is based in Santa Barbara, California. Sientra is committed to providing plastic surgeons with intuitive, elegant solutions—as reflected in its innovative round and shaped product lines. It offers breast implants, breast tissue expanders, silicone scar treatment, and additional tissue expanders.

Medical device and pharmaceutical company advancing the science and technology of corneal cross-linking

Caris Molecular Intelligence revolutionizes precision medicine to provide physicians and patients with information about their health. They develop Caris Molecular Intelligence Services that does panomic molecular profiling for oncology. Caris Life Sciences was founded with a very simple but powerful purpose – to help improve the lives of as many people as possible. Through tireless efforts, breakthrough molecular science, and a passionate commitment to quality, they remain steadfastly focused on the most important part of their work – the patient. It was founded in 1996 and is based in Irving, Texas.

Gelesis, Inc., a biotechnology company, develops therapies to treat the genesis of gastrointestinal (GI) related chronic diseases. It develops a mechanobiology technology platform to treat obesity and other chronic diseases related to the GI pathway. The company also provides PLENITY, an orally administered, non-stimulant, non-systemic aid to weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and chronic idiopathic constipation. Gelesis, Inc. was founded in 2006 and is based in Boston, Massachusetts.

Zai Lab is a Shanghai-based biopharmaceutical company with a goal of bringing transformative medicines to China and discovering and developing therapeutics for patients worldwide.

Ornim, Inc. develops medical monitoring tools for the measurement of blood flow and oxygen saturation in patients. The company offers CerOx, a non-invasive monitor, which provides real-time data on oximetry and blood flow measurements of specific tissue. Its products are used for applications in neurological treatments and cardiac surgery. The company was founded in 2004 and is based in Santa Clarita, California. It has a research and development subsidiary operation in Israel.

Attenua, Inc. is a virtual biotech company formed to develop therapies for debilitating conditions neglected by Big Pharma's shift to specialty Pharma and biologics. They believe small molecule Blockbuster drugs that would benefit millions are still to be discovered. They have assembled a team of leading scientists and ex-Big Pharma advisors with many years of drug development expertise. Their team has previous work experience at Merck, GSK, AstraZeneca, and Genentech.

As of March 13, 2019, Arsanis, Inc. was acquired by X4 Pharmaceuticals Inc., in a reverse merger transaction. Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases in the United States. The company engages in the development of ASN500, a mAb that is in preclinical development targeting respiratory syncytial virus (RSV), a virus that can cause respiratory tract infections in young children and elderly, and immunocompromised patients. Its pipeline also comprises mAbs targeting various serious bacterial and viral pathogens, including Staphylococcus aureus and RSV. In addition, the company’s preclinical stage Gram-negative mAb programs include ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

BiomX discovers and develops innovative microbiome therapeutics. The Company's mission is to develop novel therapeutics for preventing and treating diseases in which microbiome imbalances have been implicated. BiomX's microbiome modulation technologies are based on the cutting-edge innovative research of its scientific collaborators: Professor Rotem Sorek, PhD and Dr. Eran Elinav, MD, PhD both of the Weizmann Institute of Science and Professor Timothy K. Lu, MD, PhD of the Massachusetts Institute of Technology.

Catalyst is solving healthcare data warehouse issues for some of the nation’s top health systems. With the shift from paper to electronic records, it has become a challenge to organize health data, make sense of it, and to do it quickly. Catalyst helps organize, normalize, and link the data from all different systems. And they make it searchable by all users, even the non-technical, by using rich metadata capabilities.

Neurogastrx, Inc. manufactures biopharmaceutical products for the treatment of gastrointestinal disorders. The company develops product such as NG101 that increases gastric motility and contains antiemetic properties. Neurogastrx, Inc. was incorporated in 2017 and is based in Campbell, California.

LifeCell is a private stem cell bank that brings the concept of umbilical cord stem cell banking to India. Set up in the year 2004, LifeCell started out as an umbilical cord stem cell banking company and has now grown to become a comprehensive stem cells solutions provider with a complete spectrum of services including multi-service stem cell banking, R&D, stem cell clinical trials, and stem cell therapy. Based in Chennai, LifeCell has a spread over 100 service centers in India and the GCC countries.

Otic Pharma is a clinical-stage pharmaceutical company focusing on the development and commercialization of products for disorders of the ear, nose, and throat (ENT). The company has two platform technologies, each of which has the potential to be developed for multiple ENT indications. The company is currently developing a nasally-administered, combination drug product (OP-02) intended to address the underlying cause of otitis media and Eustachian tube dysfunction (OM/ETD), a condition that affects more than 700 million people around the world every year. Otitis media is one of the most common disease seen in pediatric practice and the most frequent reason children consume antibiotics or undergo surgery. The company also has a foam-based drug delivery technology platform (OP-01) that can be used to deliver drugs into the ear, nose, and sinus cavities. The company is currently developing OP-01 as an improved treatment option for acute otitis externa (“swimmers ear”). For more information on the company, please visit www.oticpharma.com

As of March 13, 2019, Arsanis, Inc. was acquired by X4 Pharmaceuticals Inc., in a reverse merger transaction. Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases in the United States. The company engages in the development of ASN500, a mAb that is in preclinical development targeting respiratory syncytial virus (RSV), a virus that can cause respiratory tract infections in young children and elderly, and immunocompromised patients. Its pipeline also comprises mAbs targeting various serious bacterial and viral pathogens, including Staphylococcus aureus and RSV. In addition, the company’s preclinical stage Gram-negative mAb programs include ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Tricida, Inc. is a late-stage pharmaceutical company focused on the development and commercialization of its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. Metabolic acidosis has been associated with increased muscle wasting, loss of bone density and death.

Amnis Corporation engages in the development, manufacture, and marketing of cell analysis systems for the imaging and analysis of cells in flow. It provides ImageStream, an instrument that combines the functionalities of microscopy and flow cytometry in a single platform for various applications in drug discovery, basic biomedical research, and diagnostics. The company also offers upgrades for ImageStream system to add additional functionality, including violet and red lasers, and an extended depth of field technology (EDF) option. In addition, it provides IDEAS, a cell image analysis software that is used for the quantitative analysis of cell images, as well as for the evaluation of image-based data in various cell populations. Further, the company provides a calibration reagent for the operation of ImageStream system that allows the instrument to track flow rate and core position; and a sheath solution for the functioning of ImageStream system. Its systems are used in apoptosis, immune synapse analysis, nuclear translocation, leukocyte classification, cell cycle analysis, cell morphology analysis, intracellular molecular trafficking, surface markers co-localization, and gene expression quantitation applications. The company offers its products to academic, biotechnology, and pharmaceutical customers. Amnis Corporation was founded in 1998 and is headquartered in Seattle, Washington.

Humacyte, Inc., a medical research, discovery, and development company, focuses on developing and commercializing a proprietary technology based on human tissue-based products for application in regenerative medicine and vascular surgery. It designs acellular extracellular matrices, which are formed in vitro from banked vascular smooth muscle cells and decellularized to eliminate the risk of rejection; and used as tissue-engineered grafts for patients in need of vascular repair or replacement. The company was incorporated in 2004 and is headquartered in Morrisville, North Carolina.

Passage Bio, Inc., a genetic medicines company, focuses on developing transformative therapies for rare monogenic central nervous system (CNS) diseases. It has research, collaboration, and license agreement with the University of Pennsylvania and its gene therapy program; and The Trustees of the University of Pennsylvania for research and development collaborations, and exclusive license rights to patents for certain products and technologies. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.

Garuda Therapeutics is developing off-the-shelf hematopoietic stem cell (HSC) therapies to treat a broad range of severe and life-threatening diseases.

ABIONYX Pharma SA, a biopharmaceutical company, discovers and develops high density lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. The company is developing a portfolio of HDL therapies, which include HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients. It is developing CER-001, an engineered complex of recombinant human apoA-I, the structural protein of HDL, and phospholipids that is in Phase II clinical trials designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; and CER-209, a drug candidate that is in Phase I clinical trial for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Labege, France.

Acutus Medical develops medical technologies to treat complex cardiac arrhythmia. The company's platform displays the heart’s true activation pattern, turning the chaos of a complex arrhythmia into a clear vision for electrophysiologists. Acutus Medical is a privately funded company founded in 2011 and based in Carlsbad, California. Its products are co-developed in the U.S. and Europe with an exceptional team of medical scientists, biomedical engineers, and other professionals. It was founded in 2011 and headquartered in Carlsbad, California.

Alpine Immune Sciences is an immunotherapy startup focused on developing recombinant, protein-based therapeutic solutions. It was founded on January 23, 2015, and is based in Seattle, Washington, United States.

Pieris Pharmaceuticals, Inc. is a, clinical-stage biotechnology company applying its proprietary Anticalin® technology to create differentiated drugs that can help patients suffering from cancer, severe asthma, anemia and other medical conditions with a high unmet medical need. Anticalins are recombinantly engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. Our libraries of more than 100 billion different Anticalins can virtually bind to any target of interest.

Emergence Therapeutics AG develops novel antibody drug conjugate (ADC) immuno-therapeutics to treat high need cancers. The company was incorporated in 2019 and is based in Duisburg, Germany.

KANDY THERAPEUTICS LIMITED develops non-hormonal treatment for multiple symptoms of the menopause including hot flashes and night time awakening. The company offers NT-814, a drug for common, chronic debilitating female sex-hormone related treatment. It provides non-hormonal therapy to treat moderate to severe post-menopausal vasomotor symptoms, enabling patients to receive treatment, and reduce symptoms of hormone related conditions. The company was founded in 2017 and is based in Stevenage, United Kingdom. KANDY THERAPEUTICS LIMITED operates as a subsidiary of Bayer Aktiengesellschaft.

Vigil will use the Series A funds to progress its lead pipeline candidate, a monoclonal antibody TREM2 agonist, through Phase 1 studies, advance their small molecule TREM2 agonist to IND, as well as pursue additional assets to grow the pipeline and increase the body of data supporting microglia biology as an important therapeutic pathway.

Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism.

Alpine Immune Sciences is an immunotherapy startup focused on developing recombinant, protein-based therapeutic solutions. It was founded on January 23, 2015, and is based in Seattle, Washington, United States.

Ventyx Biosciences is a biotechnology company with a diverse portfolio of best-in-class highly differentiated clinical and pre-clinical stage programs focused on high-value targets.

ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of cystic fibrosis. They have combined selected tRNAs with their unique and diverse proprietary delivery platforms to create and develop first-in-class suppressor tRNA-nanoparticle therapeutics for correcting nonsense mutations. ReCode’s diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF). The company’s proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing. The company was founded in 2015 and is based in Dallas, Texas.

resTORbio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases.The Company develops medicines and therapies to treat aging-related diseases and conditions such as cancer, heart disease, neurodegenerative diseases, and diabetes mellitus. resTORbio serves clients in the State of Massachusetts.

Century Therapeutics, Inc. engages in the development of induced pluripotent stem cell- (iPSC) based drugs for the treatment of hematologic and solid malignancies. The use of iPSC enables multiple rounds of cellular engineering to produce master cell banks of modified cells that can be expanded and differentiated into immune effector cells to supply allogeneic, homogeneous therapeutic products. The company was founded in 2018 and is based in Philadelphia, Pennsylvania.

Novellusdx develops tumor specific driver mutations. It focuses on testing targeted therapy drugs on emulated tumors and quantifying their therapeutic effect, monitoring the oncogenic activity of the patient's relevant genes and proteins, and monitoring the oncogenic activity before and after drug administration. Novellusdx develops assays that detect disregulated translocation of mutated signaling proteins to the nucleus; and measures the impact of a drug or drug candidate on a specific tumor, specifically in terms of its ability to inhibit the up-regulated signaling protein translocation to the nucleus. Haim Gil-ad and Yoram Altschuler founded it on May 1, 2011, with its headquarters in Jerusalem in Israel.

Emphasys Medical develops therapeutic devices for the treatment of patients with emphysema and other breathing disorders. It offers Zephyr Endobronchial Valve system, which is designed to block air from passing through the opening in the lung and into the chest cavity, resulting in the reduction or elimination of airflow through the leak to allow the tissue to heal. Emphasys Medical was founded in 2000 and is based in Redwood City, California.

Practice Fusion is a cloud-based electronic health records company in the U.S. for independent practices. Its mission is to connect doctors, patients, and data to drive better health and save lives. The company was founded in 2005 and is headquartered in San Francisco, California.

ViewRay, Inc. designs, manufactures, and markets radiation therapy systems. The company offers MRIdian, a magnetic resonance image guided radiation therapy system to image and treat cancer patients. Its MRIdian integrates MRI technology, radiation delivery, and proprietary software to see the soft tissues, shape the dose to accommodate for changes in anatomy, and strike the target using real-time targeting throughout the treatment. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. markets its MRIdian through a direct sales force and distribution network. It has operations in the United States, France, Germany, and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

scPharmaceticals is creating innovative and important new therapeutic options by administering drugs subcutaneously using a convenient two component delivery system suitable for patient self-administration.In February 2013 scPharmaceuticals was formed to continue the groundbreaking work of SpringLeaf Therapeutics, a Boston area company that started in 2007. scPharmaceuticals targets the untapped opportunity of treating patients with serious medical conditions with a convenient safe and comfortable subcutaneous administration of a drug. This is therapeutically equivalent to intravenous administration while avoiding the cost, burden and risks associated with intravenous administration.

ABIONYX Pharma SA, a biopharmaceutical company, discovers and develops high density lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. The company is developing a portfolio of HDL therapies, which include HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients. It is developing CER-001, an engineered complex of recombinant human apoA-I, the structural protein of HDL, and phospholipids that is in Phase II clinical trials designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; and CER-209, a drug candidate that is in Phase I clinical trial for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Labege, France.

Singulex, Inc., a biotechnology company, develops and commercializes direct molecular detection technology solutions. Its solutions enable life science researchers and clinicians to understand and manage disease. The company develops biomarker diagnostic systems that can detect and quantify normal and abnormal protein biomarkers. It is conducting pilot studies to validate Erenna BioAssay System, a digital molecule detection platform, which detects and quantifies molecule biomarkers in clinical samples. The company also offers various custom assay services, such as pilot study services, assay prototyping, assay characterization, and assay validation. The company was formerly known as BioProfile Corporation and changed its name to Singulex, Inc in September 2003. Singulex is based in Hayward, California

Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief. Q32 Bio consists of a team of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies.

Pionyr Immunotherapeutics is developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity. The company is exploiting novel target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics. The company’s approach, Myeloid Tuning™, is designed to enhance the immune system’s anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity.

Erasca develops oncology drugs intended to provide precision oncology options. The company's drugs are being developed through multiple discovery programs for undisclosed targets that are biological drivers of cancer and are pursuing additional opportunities for pipeline expansion through academic and biopharmaceutical collaborations, providing patients with new potential solutions to not just treat but cure cancer. It was founded in 2018 and headquartered in San Diego, California.

CBT Pharmaceuticals is an emerging life sciences oncology company focused on developing innovative medicines targeting the growth and proliferation of cancer cells for which available treatments are inadequate. Our pipeline is comprised of four development-stage assets – an oral agent that specifically targets cancer metastasis, a pre-clinical candidate that targets uncontrolled growth signaling pathways, and two investigational products that restore the body’s immune system to recognize and kill cancer cells.

Avitide, Inc. discovers, manufactures, and supplies molecule-specific affinity purification solutions for the biopharmaceutical industry. It offers affinity separation technology that enables customers to achieve bioprocess development timelines, reduce program risk, predict commercial scalability, and reduce manufacturing costs. The company also develops affinity purification solutions for the manufacturing of life-saving therapeutics, including enzymes, novel scaffolds, multi-specific antibodies, gene therapies, and vaccines. Avitide, Inc. was incorporated in 2012 and is based in Lebanon, New Hampshire.

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California.

ChemoCentryx focuses on discovery, development and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors. Their small molecule product candidates is designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.

GentiBio, Inc. develops engineered regulatory T cells (EngTregs) for the treatment of autoimmune, alloimmune, autoinflammatory, and allergic diseases. Its proprietary autologous and allogeneic EngTregs platform integrates key complementary technologies needed to restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics. The company was incorporated in 2020 and is based in Boston, Massachusetts. It has additional locations in Israel and Seattle, Washington.

Arrail Dental Clinic is specialized in providing oral health care services to its clients both home and abroad. So far, Arrail has set up thirty branches in central business districts in first and second-tier cities in China such as Beijing, Shanghai, Shenzhen, Guangzhou, Xiamen, Hangzhou, and Tianjin. It also provides a broad platform for elite dentists all over the world.

Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns. Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called Lung EpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel.

Terns Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops molecularly targeted, oral, small-molecule drugs to treat cancer and liver diseases. Its products includes TERN-101, a potent non-bile acid farnesoid X receptor agonist and TERN-201, a semicarbazide-sensitive amine oxidase inhibitor. The company was founded in 2017 and is based in Foster City, California with additional offices in Shanghai, China.

NewMed Medical Co., Ltd. engages in the research, development, manufacture, and marketing of interventional artificial heart valve systems. Its products include artificial heart valves and transcather implantation systems. The company was founded in 2015 and is based in Shanghai, China.

Syros Pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. Syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical R&D. Central to the Syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of Syros' senior leadership. While this scientific approach has applications in many therapeutic areas, Syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.

Civitas Therapeutics is a biopharmaceutical company that focuses on developing pulmonary delivery therapies. The Company develops therapeutics for the treatment of central nervous system and respiratory disorders. It serves patients throughout the United States.

Treato Ltd. operates Treato, provides social health patient intelligence solutions. The company offers health information platform that aggregates patient experiences from the Internet; and organizes them into usable insights for patients, healthcare professionals, pharma companies, and other healthcare organizations. Its Treato platform collects data from healthcare social media sites and forums; analyzes the information; and provides a window into patients’ thoughts and attitudes. The company also provides Treato Pharma, a brand intelligence service for pharma marketers and agencies to provide analytics and insights into patients’ thoughts and attitudes. Its Treato Pharma also interprets the patient voice, understands patient behaviors, gains competitive insights, extracts the right messages, expends effort into the right places, and engages in real time. Treato Ltd. was founded in 2008 and is based in Yehud, Israel.

Predix is a drug discovery and development company that uses a novel 3D Discovery and Optimization Engine for GPCR drug candidates and is taking its novel compounds into the clinic. The discovery engine uses a sophisticated proprietary algorithm, PREDICT(TM), for computer modeling the 3D structure of any GPCR target; advanced technologies HYPERION(TM) and RISS(TM) for rapid high-throughput in silico screening of millions of compounds against the 3D in silico model of the target; and an integrated medicinal/computational platform for lead optimization based on the receptor's structure (ICELR-3D(TM)) and predictive algorithms for important drug properties. In August, Predix and Physiome Sciences Inc. combined companies and expanded the expertise into ion channel drug discovery.

Entos uses machine learning-technology for energy and force evaluations required for R&D labs. Its technology assists in analyzing quantum molecular simulation. The software uses mean-field-cost quantum calculations to analyze the data for the atomic representation of the molecules and can detect molecular spaces in a molecule. One of the products of the company is the Qcore Simulation Engine that assists with the molecular detection and modeling process.

Gemini Therapeutics is a precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases.Their therapeutic candidates are matched to molecular abnormalities found in patients with high clinical need and our broad multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. Launched with funding from leading life science investors and powered by academic partnerships around the world,they are developing a series of potentially first-in-class therapeutics.

Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns. Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called Lung EpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel.

Decibel Therapeutics is a developer of hearing disorder therapeutics intended to protect, repair and restore hearing. The company's therapeutics have provided insights into the link between hearing dysfunction and inner ear pathology and it has capabilities to encompass animal models, drug delivery to the inner ear, imaging, inner ear PK/PD modeling and measurement, bioinformatics, genetics and target identification, enabling patients to experience hearing loss therapies with different forms of hearing disorders for their recovery.

XinThera is a drug discovery company focused on building small molecule oncology and immunology pipeline.

Cerapedics, Inc., an orthobiologics company, develops and commercializes its proprietary synthetic small peptide technology platform. It offers i-FACTOR, a peptide enhanced bone graft in orthopedics that incorporates a small peptide as an attachment factor to stimulate the natural bone healing process; and i-FACTOR+ MATRIX for surgical implantation. Cerapedics, Inc. was founded in 2000 and is headquartered in Westminster, Colorado with an additional office in Denver, Colorado.

VIVUS, Inc. is a drug-development company dedicated to the development and commercialization of next-generation therapeutic products addressing obesity, diabetes, sleep apnea and sexual health.

Turning Point Therapeutics, Inc. is a clinical-stage structure-based drug design company for the discovery and development of precision medicines for cancer and other diseases. We are focusing on the design of novel chemical identities for established oncogene drivers with secondary resistant mutations, newly identified disease-driven targets, and potential targets regulating tumor microenvironment and tumor immunity.

Adagio Therapeutics, Inc., a biotechnology company, develops antibodies that neutralize SARS-CoV-2, SARS-CoV-1, and potentially emergent coronaviruses. Its portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

Novellus is a biotechnology company working to develop engineered cellular medicines. The company uses its non-immunogenic mRNA molecules to reprogram and gene-edit cells safely, and with high efficiency. They engineer precision medicines for patient segments and select from its technology toolbox for in vivo, ex vivo, allogeneic and autologous delivery. Novellus platform enables the high-level expression of gene-editing and cell-reprogramming proteins for high-specificity gene repair and both autologous and allogeneic cell therapies. The company is advancing its lead program, a breakthrough therapy for a rare dermatologic disease, through pre-clinical studies. Novellus was founded in 2015 and is headquartered in Cambridge, Massachusetts, United States.

NeRRe Therapeutics Ltd. develops preclinical and clinical neurokinin (NK) receptor antagonists. The company focuses on NK-1 antagonist asset orvepitant as an oral treatment for intense pruritus induced by targeted anti-cancer therapies. It offers NT-814, a NK-1, 3 antagonist; NT-949, a Phase I ready NK-1 antagonist; and NT-432, a NK-1 antagonist clinical candidate. The company was founded in 2012 and is based in Stevenage, United Kingdom.

ArriVent is dedicated to accelerating the global development of innovative biopharmaceutical products.

Binx Health Limited, an in vitro diagnostics company, develops and provides diagnostic instrument and disposable cartridge systems for decentralized laboratory, point-of–care, and other near-patient settings. It offers io System, a diagnostic platform that is designed to detect the presence of infectious diseases, such as chlamydia and MRSA; and Callisto, a system that provides a solution to meet a range of throughput requirements. The company provides solutions for sexually transmitted infections and hospital acquired infections. Binx Health Limited has a strategic partnership with Sherlock Biosciences. The company was founded in 2005 and is based in Trowbridge, United Kingdom.

Biocytogenan advanced biotechnology company located in Beijing's Economic and Technological Development Zone, was founded in November 2009 by a team of scientists who have multiple years’ experience developing animal models and operating Biocytogen USA. Biocytogen's goal is to become the leading gene targeted animal model and service supplier globally. Biocytogen efficiently integrates the advanced capabilities and resources available in both China and the USA. Biocytogen has established two excellent gene-targeting platforms. The first is a traditional ESC/HR platform that includes a unique gene targeting vector construction technology with an accurate micro-injection system and high germline transmission efficiency of C57BL/6 mouse embryonic stem cells (ESC).

Abbisko Therapeutics Co. Ltd. discovers, develop, and manufactures immuno-oncology therapies. It offers ABSK011 and ABSK021, which are molecule inhibitors for treating hepatocellular carcinoma; and CSF1R for the treatment of solid tumors. The company also develops therapeutics for the treatment of cancer, tumor, and diabetes, metabolic diseases, liver diseases, viral infections and CNS diseases. The company was founded in 2016 and is based in is based in Shanghai, China.

CryoCor, Inc. is a medical technology company headquartered in San Diego, California developing products that use cryogenic technology to treat cardiac rhythm disorders called arrhythmias. Cardiac cryoablation is a non-surgical, minimally-invasive procedure in which a cardiologist inserts a catheter into a blood vessel in the leg of an afflicted individual and advances it into the heart. Once it reaches the targeted cardiac tissue, the catheter tip temperature is lowered to approximately -90°C — thereby blocking the conduction of the abnormal signals causing the heart to beat inappropriately and restoring its function to normal. The CryoCor™ Cardiac Cryoablation System consists of a cryoablation catheter that is connected to an articulating arm mounted on the company’s refrigeration console. To facilitate catheter placement, the System can be used in conjunction with CryoCor introducer sheaths. The System has been approved for use in Europe and has been commercially available there since 2002. CryoCor's European activities are managed by its wholly-owned subsidiary in Cologne, Germany which directs the company's marketing, sales and post-market clinical activities. The CryoCor Cardiac Cryoablation System is currently in use at multiple medical centers throughout Europe.

Medigus Ltd., a medical device company, develops, produces, and markets minimally invasive endo-surgical tools and direct visualization technology in the United States, Europe, Asia, and internationally. It offers Medigus Ultrasonic Surgical Endostapler, an endoscopy system, which is used for the treatment of gastroesophageal reflux disease. Medigus Ltd. was founded in 1999 and is headquartered in Omer, Israel.

Adaptive Biotechnologies is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clone-SEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers. It was founded in 2009 and headquartered in Seattle, Washington.

Caris Molecular Intelligence revolutionizes precision medicine to provide physicians and patients with information about their health. They develop Caris Molecular Intelligence Services that does panomic molecular profiling for oncology. Caris Life Sciences was founded with a very simple but powerful purpose – to help improve the lives of as many people as possible. Through tireless efforts, breakthrough molecular science, and a passionate commitment to quality, they remain steadfastly focused on the most important part of their work – the patient. It was founded in 1996 and is based in Irving, Texas.

Tricida, Inc. is a late-stage pharmaceutical company focused on the development and commercialization of its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. Metabolic acidosis has been associated with increased muscle wasting, loss of bone density and death.

Zai Lab is a Shanghai-based biopharmaceutical company with a goal of bringing transformative medicines to China and discovering and developing therapeutics for patients worldwide.

Sonendo developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science®. The GentleWave® System shows significant improvements in clinical efficacy and practice efficiency when compared to standard root canal treatment.1,2, 3 Sonendo is the parent company of TDO® Software, the developer of the most widely used endodontic practice management software in the world, designed to simplify practice workflow. TDO software seamlessly integrates practice management, imaging, social media, referral reporting, CBCT imaging, and offers built-in communication with the GentleWave System.

Stemirna Therapeutics is a RNA technology based drug development company designed to maximize the potential of RNA science. The company currently has more than a dozen of independently-developed mRNA drug projects, focusing on the fields of mRNA-based personalized cancer vaccines, mRNA vaccines for infectious disease, protein defects diseases, and genetic diseases, providing cure and solutions for cancer and infectious diseases, better serving patients.

Pieris Pharmaceuticals, Inc. is a, clinical-stage biotechnology company applying its proprietary Anticalin® technology to create differentiated drugs that can help patients suffering from cancer, severe asthma, anemia and other medical conditions with a high unmet medical need. Anticalins are recombinantly engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. Our libraries of more than 100 billion different Anticalins can virtually bind to any target of interest.

PMV Pharma is developing first-in-class p53 and p53 pathway modulators for the treatment of cancer. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.

Acutus Medical develops medical technologies to treat complex cardiac arrhythmia. The company's platform displays the heart’s true activation pattern, turning the chaos of a complex arrhythmia into a clear vision for electrophysiologists. Acutus Medical is a privately funded company founded in 2011 and based in Carlsbad, California. Its products are co-developed in the U.S. and Europe with an exceptional team of medical scientists, biomedical engineers, and other professionals. It was founded in 2011 and headquartered in Carlsbad, California.

Audentes Therapeutics is a biotechnology company committed to the development and commercialization of innovative new gene therapy treatments for people with serious rare diseases. We are a focused, experienced and passionate team driven by the goal of improving the lives of patients.

BioLineRx is a clinical-stage, publicly-traded (NASDAQ/ TASE: BLRX) biopharmaceutical development company based in Jerusalem, Israel. The Company develops products suitable for the pharmaceutical market satisfying an unmet medical need or exhibiting advantages over current therapies.

Cerimon Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics for autoimmune diseases, inflammation, and pains in the United States and Europe. It develops Simulect, a monoclonal antibody for the treatment of moderate-to-severe and steroid-refractory ulcerative colitis; diclofenac sodium, a non-steroidal anti-inflammatory drug that are used to treat various pains, including pain due to musculoskeletal injuries and lower back pain; and topical diclofenac sodium patch products. Cerimon Pharmaceuticals, Inc. was founded in 2004 and is headquartered in South San Francisco, California.

Cardioxyl Pharmaceuticals is a privately held, clinical stage biopharmaceutical company developing therapies for the treatment of cardiovascular disease, focusing on the discovery, development and commercialization of novel technologies for disease areas where current therapies don't exist, are ineffective or are inadequate. Cardioxyl has developed industry-leading expertise in the chemistry, biology and clinical applications of nitroxyl technology. The company's core nitroxyl platform has generated several pre-clinical and clinical candidates including the company's lead compound, CXL-1020, currently in clinical development for Acute Decompensated Heart Failure, the most common cause of hospitalization for patients older than 65 years of age.

PharmEasy is - Pharmacy made Easy. We are one of the largest pharmacy aggregators in India. We help patients connect with local pharmacy stores and diagnostic centres in order to fulfil their extensive medical needs. We believe that everyone should have access to good health.

Treeline Biosciences is a biotech company building transformative precision medicines for patients with cancer and other serious conditions. The company was founded in 2021 and is headquartered in Stamford, CT.

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients living with rare neurological disorders. Its lead product includes WAKIX (pitolisant) for the treatment of pediatric patients suffering from narcolepsy. Harmony Biosciences Holdings, Inc. was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. The company was founded in 2017 and is based in Plymouth Meeting, Pennsylvania.

Prelude Therapeutics is a developer of novel therapies intended to target key drivers of cancer cell growth, survival, and resistance. The company's offerings include developing a pipeline of novel, orally bioavailable, small-molecule therapies to target critical intervention points in pathways of resistance to overcome treatment failure in cancer, enabling healthcare providers to discover potential treatments that offer hope to people with cancer. Prelude Therapeutics was founded in 2016 by Krishna Vaddi and is based in Wilmington, Delaware.

Aspen Neuroscience, Inc. develops induced pluripotent stem cells to treat neurological conditions. Its products pipeline includes ANPD001, an autologous neuron replacement therapy in sporadic Parkinson disease; and ANPD002, a gene-edited autologous neuron replacement therapy for familial forms of Parkinson disease. The company was incorporated in 2018 and is based in San Diego, California.

Scribe Therapeutics Inc. engages in the engineering, delivery, and development of in vivo therapies and CRISPR molecules to rewrite and repair the underlying cause of genetic disorders. Its technology includes X-Editing (XE), an engineered molecule for therapeutic use and in vivo genetic modification. The company was incorporated in 2017 and is based in Berkeley, California.

Arteaus Therapeutics, LLC, a Cambridge, Massachusetts-based biotechnology development company focused on creating new therapies for migraine prevention.

ChemomAb is a clinical stage biopharmaceutical company, founded in 2011. ChemomAb specializes in the development of proprietary monoclonal antibodies, directed towards novel targets, for the treatment of immune-mediated and fibrotic disorders including orphan indications. The leading compound, CM-101, was selected after meticulous testing in a series of pre-clinical animal models simulating human disorders and has shown promising safety and efficacy as well as a novel mechanism of action.

Compass Therapeutics is a clinical-stage biotechnology company targeting the human immune synapse with a new generation of antibody therapeutics. Compass has broadly drugged the immune system by generating epitopically diverse antibody panels to more than 40 targets across all immune cell types and is leveraging its proprietary StitchMabs and common light-chain based multispecific platforms to empirically identify combinations and multispecific with optimized activity. The company’s lead product candidate, CTX-471, is a fully human agonistic antibody of CD137, which is in a Phase 1 study in patients with inadequate responses to PD-1/PD-L1 checkpoint inhibitors. Compass is also progressing several preclinical assets including a novel class of NK cell engagers targeting NKp30 and multiple bispecific checkpoint programs. The company’s offices and labs are based in Kendall Square in Cambridge, Mass.

Ventyx Biosciences is a biotechnology company with a diverse portfolio of best-in-class highly differentiated clinical and pre-clinical stage programs focused on high-value targets.

At Graphite Bio, they are rapidly building a next-generation gene editing company that is driven to apply their breakthrough technology with urgency to advance gene replacement therapies and cures for people living with serious diseases. They stand apart through our ability to harness natural and highly precise cellular DNA repair machinery to achieve high efficiency, targeted gene integration to correct the underlying causes of diseases.

ChemomAb is a clinical stage biopharmaceutical company, founded in 2011. ChemomAb specializes in the development of proprietary monoclonal antibodies, directed towards novel targets, for the treatment of immune-mediated and fibrotic disorders including orphan indications. The leading compound, CM-101, was selected after meticulous testing in a series of pre-clinical animal models simulating human disorders and has shown promising safety and efficacy as well as a novel mechanism of action.

TigerConnect is a provider of clinical communication solutions, TigerConnect helps physicians, nurses, and other staff communicate and collaborate more effectively, accelerating productivity, reducing costs, and improving patient outcomes. Trusted by more than 4,000 healthcare organizations, TigerConnect maintains 99.99% uptime and processes over 10 million messages each day. Its category-leading product innovations and advanced integrations with critical hospital systems deliver high value for hospitals and large health systems. Their commitment to client success is reflected in their broad support organization that works directly with clients at every stage to streamline communication workflows and achieve the highest possible ROI. The company was incorporated in 2010 and is headquartered in Santa Monica, California.

X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment. The company is developing two unique programs such as drug candidate, X4P-001, has clinical experience in over 70 subjects, and is advancing into Phase 1/2 trials in refractory clear cell renal cell carcinoma (ccRCC) and refractory epithelial ovarian cancer (EOC), the second program, X4P-002, is a unique series of late lead molecules that penetrate the blood-brain barrier. They will pursue early clinical development in glioblastoma multiforme (GBM), a rare form of lethal brain cancer, for the X4P-002 program. X4 Pharmaceuticals was founded in 2014 and is based in Cambridge, Massachusetts, United States.

MDClone Ltd. designs and develops software that analyzes medical records. Its software platform creates synthetic medical records for fictitious patients, avoiding the risk of public disclosure of actual medical data. The company’s platform enables researchers to examine the behavior of the disease, doctors, drugs, and health organizations without risking private patient medical data. MDClone Ltd. was founded in 2016 and is based in Beersheba, Israel.

RayzeBio, Inc. is a biotechnology company that develops tumor-targeted small molecule medicines that harness the power of radioisotopes. The company provides macrocyclic peptide mimetic binders to deliver therapeutic radioisotopes, such as Actinium-225, an alpha-emitter for solid tumors. RayzeBio, Inc. was founded in 2020 and is based in San Diego, California.

Guangzhou Baseline Medical is committed to building a world-class clinical application of high-throughput sequencing and R & D platform to become the leading global provider of precision medical solutions. The company's core team has more than 20 years of senior industry experience, involved in cancer genomics, genetics and bioinformatics and other fields. Based on its core technical advantages, the Company aims at precision medicine, establishes a cooperative relationship with middle and downstream enterprises in the industry, and forms a complete industrial chain from academic research to clinical product transformation. It has also established close cooperation with many large-scale third-party inspection agencies including Illumina, Well-known domestic and foreign hospitals and research institutes to establish cooperative relations, the development of a series of independent intellectual property rights and international competitiveness of clinical testing products for patients, doctors and medical institutions to provide accurate, convenient and comprehensive services.

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was founded in 2017 and is headquartered in Boulder, Colorado.

Established in 1992 as Suraksha Diagnostics & Eye Centre (P) Ltd. in Kolkata, they started as one of the first diagnostic centers in Kolkata to provide all pathology and radiology services under one roof. This convenience, along with their unwavering commitment to accuracy and service, resulted in steady growth and popularity. Within 3 years they could confidently open a second Center at Siliguri, in North Bengal, which remains the largest such facility in the region, and today serves not only to patients from North Bengal, but also neighbouring States and countries. Since then they have grown steadily across Bengal, Bihar, and Delhi NCR.

Selecta Biosciences is a biopharmaceutical company developing the first generation of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Their proprietary product platform technology combines recent advances in immunobiology with cutting-edge nanotechnology to develop targeted immunomodulatory nanoparticles. It was founded in 2008 and is headquartered in Watertown, Massachusetts.

Medical device and pharmaceutical company advancing the science and technology of corneal cross-linking

Complete Genomics' high quality, affordable DNA sequencing enables commercial-scale research of the genetic mechanisms underlying drug responses and complex diseases. Complete Genomics combines innovative technology with a disruptive market approach that will revolutionize DNA sequencing.

Delfi Diagnostics detect cancer early, when it is most curable, using high precision non-invasive blood tests. It uses artificial intelligence and genome sequencing to detect unique patterns of DNA fragmentation in the blood of patients. It was founded in 2019 and is headquartered in Baltimore, Maryland.

E-Scape Bio, Inc., a biopharmaceutical company, discovers and develops small molecule therapies to treat genetically defined subpopulations in neurodegenerative diseases. Its programs improve the lives of patients suffering from Alzheimer’s disease, Parkinson’s disease, and sphingolipid storage disorders. E-Scape Bio, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Cynapsus is a pharmaceutical company that focuses on developing a non-injectable drug for Parkinson’s disease. The company specializes in the fields of healthcare, biotechnology, pharmaceutical, and therapeutics. It was founded in 2004 and headquartered in Toronto, Ontario.

GrayBug is a pharmaceutical company that focuses on developing the next generation of products for the treatment of chronic vision-threatening diseases of the retina and optic nerve. The company is currently developing a continuum of proprietary micro – and nanoparticle controlled release technologies and implants for strategic partnership and its own therapeutic products for major ocular disease indications including wet AMD and Glaucoma. The company was founded in 2011 and headquartered in Baltimore, Maryland.

SteadyMed Ltd. is a medical-device company pursuing innovative devices for delivering injectable therapeutic drugs for pain relief, diabetes and other chronic conditions. The company's products are pre-filled drug-infusion patches that will be sold in conjunction with a series of pharma and device companies. Specific applications of the device will be tailored in accordance with the requirements of the company's partners.

Ikena Oncology is dedicated to bringing next generation oncology therapies to patients suffering from cancer. Ikena Oncology are committed to leveraging our unique understanding of the complex biologic pathways that drive the formation and spread of cancers to discover and develop novel, patient-directed therapies. Selecting patients for treatment in clinical studies with biomarkers we develop is at the core of our strategy.

ReViral is a developer of antiviral drugs designed to help patients and enlarge the antiviral market by developing novel first-in-class compounds. The company's antiviral drugs is a fusion inhibitor of RSV which is a highly potent, novel small molecule and is being developed to treat RSV in patients with severe disease including neonates, enabling patients to be treated who are infected with respiratory syncytial virus (RSV) by developing novel compounds.

Avitide, Inc. discovers, manufactures, and supplies molecule-specific affinity purification solutions for the biopharmaceutical industry. It offers affinity separation technology that enables customers to achieve bioprocess development timelines, reduce program risk, predict commercial scalability, and reduce manufacturing costs. The company also develops affinity purification solutions for the manufacturing of life-saving therapeutics, including enzymes, novel scaffolds, multi-specific antibodies, gene therapies, and vaccines. Avitide, Inc. was incorporated in 2012 and is based in Lebanon, New Hampshire.

Cerapedics, Inc., an orthobiologics company, develops and commercializes its proprietary synthetic small peptide technology platform. It offers i-FACTOR, a peptide enhanced bone graft in orthopedics that incorporates a small peptide as an attachment factor to stimulate the natural bone healing process; and i-FACTOR+ MATRIX for surgical implantation. Cerapedics, Inc. was founded in 2000 and is headquartered in Westminster, Colorado with an additional office in Denver, Colorado.

Sientra, Inc., a medical device company, develops and markets products focusing on the plastic surgery and aesthetics market. The company is based in Santa Barbara, California. Sientra is committed to providing plastic surgeons with intuitive, elegant solutions—as reflected in its innovative round and shaped product lines. It offers breast implants, breast tissue expanders, silicone scar treatment, and additional tissue expanders.

Unilife is a U.S-based medical device and technology company that designs, develops, manufactures and supplies innovative, differentiated delivery systems for injectable drugs and vaccines.

Selecta Biosciences is a biopharmaceutical company developing the first generation of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Their proprietary product platform technology combines recent advances in immunobiology with cutting-edge nanotechnology to develop targeted immunomodulatory nanoparticles. It was founded in 2008 and is headquartered in Watertown, Massachusetts.

Good Start Genetics, Inc., a molecular diagnostics company, provides genetic screening of inherited diseases. It offers EmbryVu, a preimplantation genetic screening test to improve in vitro fertilization by identifying embryos for the implantation and pregnancy. The company was founded in 2007 and is based in Cambridge, Massachusetts. As of August 4, 2017, Good Start Genetics, Inc. operates as a subsidiary of Invitae Corporation.

Galecto, Inc. develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company, founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.

SuperDimension is a privately-held medical device company that develops and markets minimally-invasive pulmonology devices that enable the diagnosis and potentially the treatment of distal lung disease. Our product line, the i·LogicTM System, includes both capital equipment and disposables, addressing a total available market of more than 8 million patients. Driven by our mission, "To be the world leader in the diagnosis and treatment of distal lung disease," we are focused on extending the capabilities of traditional bronchoscopy tools to help diagnose previously inaccessible lung lesions at an earlier stage when they may be easier to treat.

Pulnovo Medical integrates development, production and services. Our core products including use pf radiofrequency ablation technology to treat pulmonary hypertension. The high-frequency ablation equipment and intravascular catheters developed by the company are pioneer inventions with global invention patents.

Cyrus Biotechnology builds software tools to accelerate basic research in biotech, pharma, and industrial biotechnology. Cyrus Bench delivers an enterprise version of the Rosetta molecular modeling and design toolkit, with the associated array of bio-molecular computation tools. It was founded in 2014 and headquartered in Seattle, Washington.

Pacira Pharmaceuticals Inc. operates as a pharmaceutical company which engages in the development and manufacturing of injectable pharmaceutical products. Pacira Pharmaceuticals Inc. was formerly known as DepoTech Corp. was formerly as SkyePharma Inc. and changed its name to Pacira Pharmaceuticals Inc. in June, 2007. The company was founded in 1989 and is based in San Diego, California. Pacira Pharmaceuticals Inc. operates as a subsidiary of Pacira, Inc.

ARYx is a product-driven pharmaceutical company with leading expertise and significant intellectual property in the area of retrometabolic drug design. They are focused on improving the safety of oral therapies for chronic disease.

Adagio Therapeutics, Inc., a biotechnology company, develops antibodies that neutralize SARS-CoV-2, SARS-CoV-1, and potentially emergent coronaviruses. Its portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

Adiana, Inc. engages in the development and testing of transcervical sterilization system for permanent birth control. It develops Complete TCS, which consists of a radiofrequency generator, delivery catheter, and implantable matrix. The company was founded in 1997 and is based in Redwood City, California. As of March 16, 2007, Adiana, Inc. is a subsidiary of CYTYC Corp.

Visen Pharmaceuticals is a biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients in Greater China.

Puma Biotechnology, Inc., is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The Company is initially focused on the development of PB-272 (oral neratinib), a potent irreversible tyrosine kinase inhibitor, for the treatment of patients with HER2 positive metastatic breast cancer.

SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. SI-BONE, Inc. was founded in 2008 and is headquartered in Santa Clara, California.

Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness. They have pioneered Micro-Invasive Glaucoma Surgery, or MIGS, in order to revolutionize the traditional glaucoma treatment and management paradigm. They launched the iStent®, their first MIGS device, in the United States in 2012. They are leveraging their platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. They believe the iStent® is the smallest medical device ever approved by the Food and Drug Administration, or FDA, measuring 1.0 mm long and 0.33 mm wide. In June 2015, they completed an initial public offering and their shares are now traded on the New York Stock Exchange under the ticker symbol “GKOS”. The company was founded in 1998 and is based in San Clemente, California.

Domain Surgical is a medical device company that is creating energy-based surgical products for precise soft tissue cutting and coagulation. It creates energy-based equipment used in specialty surgical procedures. Its patent-pending technology produces surface-only tissue effects with energy that does not pass through the patient designed with the surgical staff in mind, for simple user-interface and training. The company manufactures and markets the FMwand Ferromagnetic Surgical System, a hemostatic dissection device that uses pure thermal energy to cut and coagulate soft tissue, without passing an electrical current through the patient. The FMwand imparts as little as 1/10th the amount of thermal injury compared to traditional electrosurgery devices. The FMwand provides fine dissection with a layer-by-layer precision that is unmatched by existing surgical technology.

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company’s lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.

Corus Pharma is a biotech and specialty drug company that focuses on respiratory and infectious diseases. In other words, it is a development stage biopharmaceutical company that focuses on the development and commercialization of novel applications and formulations of known therapeutics to treat severe respiratory diseases. The products of the company are Corus 1020 and 1030. Corus 1020 is designed to treat respiratory infections in cystic fibrosis patients, using an inhalable form of an antibiotic called aztreonam. Corus 1030 is inhaled lidocaine for the treatment of patients suffering from the severe persistent forms of asthma. Corus Pharma is a U.S.-based company that was founded in 2001 and the company was acquired by Gilead Sciences on October 22, 2006.

GentiBio, Inc. develops engineered regulatory T cells (EngTregs) for the treatment of autoimmune, alloimmune, autoinflammatory, and allergic diseases. Its proprietary autologous and allogeneic EngTregs platform integrates key complementary technologies needed to restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics. The company was incorporated in 2020 and is based in Boston, Massachusetts. It has additional locations in Israel and Seattle, Washington.

ViewRay, Inc. designs, manufactures, and markets radiation therapy systems. The company offers MRIdian, a magnetic resonance image guided radiation therapy system to image and treat cancer patients. Its MRIdian integrates MRI technology, radiation delivery, and proprietary software to see the soft tissues, shape the dose to accommodate for changes in anatomy, and strike the target using real-time targeting throughout the treatment. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. markets its MRIdian through a direct sales force and distribution network. It has operations in the United States, France, Germany, and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

CardiAQ Valve Technologies (CVT), a privately held company, is developing innovative approaches to heart valve replacement and is initially focused on transcatheter mitral valve implantation (TMVI).

Selecta Biosciences is a biopharmaceutical company developing the first generation of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Their proprietary product platform technology combines recent advances in immunobiology with cutting-edge nanotechnology to develop targeted immunomodulatory nanoparticles. It was founded in 2008 and is headquartered in Watertown, Massachusetts.

ARMO Biosciences is a biotechnology company that develops immune modulatory biologic therapeutics. The company is based in Redwood City, California.

Enobia develops therapies to treat serious genetic bone disorders for which there are no approved treatments.

Better Continuous Glucose Monitors with a Next-Generation Glucose Sensing Enzyme SmartZyme BioPharma, Inc. is a medical technology company enabling a seamless leap to better performing glucose monitoring for people with diabetes. The company is accelerating the integration of SmartZyme's next-generation glucose-sensing enzyme into continuous glucose monitoring devices. A next-generation enzyme means no more signal mediators for the most cost-effective manufacturing; no more hypoglycemic errors for a superior safety profile; and no more fingersticks for the best quality of life. SmartZyme is an OrbiMed portfolio company.

SuperDimension is a privately-held medical device company that develops and markets minimally-invasive pulmonology devices that enable the diagnosis and potentially the treatment of distal lung disease. Our product line, the i·LogicTM System, includes both capital equipment and disposables, addressing a total available market of more than 8 million patients. Driven by our mission, "To be the world leader in the diagnosis and treatment of distal lung disease," we are focused on extending the capabilities of traditional bronchoscopy tools to help diagnose previously inaccessible lung lesions at an earlier stage when they may be easier to treat.

Medical device company developing and commercializing minimally-invasive surgical tools

Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness. They have pioneered Micro-Invasive Glaucoma Surgery, or MIGS, in order to revolutionize the traditional glaucoma treatment and management paradigm. They launched the iStent®, their first MIGS device, in the United States in 2012. They are leveraging their platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. They believe the iStent® is the smallest medical device ever approved by the Food and Drug Administration, or FDA, measuring 1.0 mm long and 0.33 mm wide. In June 2015, they completed an initial public offering and their shares are now traded on the New York Stock Exchange under the ticker symbol “GKOS”. The company was founded in 1998 and is based in San Clemente, California.

Turnstone Biologics Inc., a biotechnology company, focuses on the development of viral immunotherapies to improve survival of people with cancer. Its lead candidate RIVAL-01 consists of the vaccinia virus backbone encoding three potent immunomodulators, such as Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine designed to work together to drive immune activity and re-program the microenvironment to be best suited for tumor eradication. The company was founded in 2015 and is based in Ottawa, Canada with an additional office in New York, New York.

Verona Pharma is a biotechnology company dedicated to discovering new drugs for the treatment of chronic respiratory diseases, such as asthma, allergic rhinitis (hay fever), chronic obstructive pulmonary disease (COPD) and cough.

NeuroPace, Inc. designs, develops, manufactures, and markets implantable devices for the treatment of neurological disorders with responsive stimulation. It offers RNS System, a medical device that monitors and responds to brain activity. The company’s RNS System consists of a small implantable neuro stimulator that is connected to leads that are placed in up to two seizure onset areas. NeuroPace, Inc. was founded in 1997 and is based in Mountain View, California.

DFINE Inc. develops minimally invasive therapeutic devices that are used to treat pathologies of the vertebrae, metastatic spinal tumors, and vertebral compression fractures. It offers STAR, a tumor ablation system for palliative treatment in spinal procedures by ablation of metastatic malignant lesions in a vertebral body; vertebral augmentation systems for percutaneous delivery of bone cement and the treatment of pathological fractures; and vertebroplasty systems. The company was founded in 2004 and is based in San Jose, California. As of July 6, 2016, DFINE Inc. operates as a subsidiary of Merit Medical Systems, Inc..

Amnis Corporation engages in the development, manufacture, and marketing of cell analysis systems for the imaging and analysis of cells in flow. It provides ImageStream, an instrument that combines the functionalities of microscopy and flow cytometry in a single platform for various applications in drug discovery, basic biomedical research, and diagnostics. The company also offers upgrades for ImageStream system to add additional functionality, including violet and red lasers, and an extended depth of field technology (EDF) option. In addition, it provides IDEAS, a cell image analysis software that is used for the quantitative analysis of cell images, as well as for the evaluation of image-based data in various cell populations. Further, the company provides a calibration reagent for the operation of ImageStream system that allows the instrument to track flow rate and core position; and a sheath solution for the functioning of ImageStream system. Its systems are used in apoptosis, immune synapse analysis, nuclear translocation, leukocyte classification, cell cycle analysis, cell morphology analysis, intracellular molecular trafficking, surface markers co-localization, and gene expression quantitation applications. The company offers its products to academic, biotechnology, and pharmaceutical customers. Amnis Corporation was founded in 1998 and is headquartered in Seattle, Washington.

MacroGenics, Inc., a biotechnology company, focuses on the development, manufacture, and commercialization of immunotherapeutics for autoimmune disorders, cancer, and infectious diseases. The company is developing immune-based products, including monoclonal antibodies; and vaccines to prevent infections in healthy individuals. The company's Fc engineering technology enables to improve antibody functions to eliminate cancer cells. It is also developing products around the Dual Activating ReTargeting technology. The company was founded in 2000 and is headquartered in Rockville, Maryland.

Drug discovery inspired by viruses

InventisBio is a biotech company whose product pipeline includes small molecule drug candidates for targeted therapies in lung cancer, breast cancer and gout. The company is also actively developing drugs that can be combined with other immune-oncology targeted therapies, such as PD-1 antibody, for various cancer indications. The company is co-founded by Dr. Yaolin Wang and other scientists who have previously worked at Merck and Schering-Plough, leading various drug discovery projects in oncology, metabolic and infectious disease areas.

True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The company’s lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis. True North is currently focused on Complement-mediated rare diseases in the hematologic, kidney transplant, dermatology, and neurological space. True North was formed in 2013 as a spin-out of iPierian.

Mitoconix Bio Ltd develops a novel strategy to improve mitochondrial health as a disease modifying therapeutic for neurodegenerative diseases. The company was founded in 2016 and is based in Jerusalem, Israel.

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. With accomplished and talented scientists, and top-tier investors, we are well positioned in an exciting new era of immuno-oncology.

Aragon Pharmaceuticals is a discovery-stage small molecule company focused on therapeutics for the treatment of hormone-resistant cancers, with an initial focus on prostate and breast cancer.

Pionyr Immunotherapeutics is developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity. The company is exploiting novel target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics. The company’s approach, Myeloid Tuning™, is designed to enhance the immune system’s anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity.

Relypsa, Inc. is a privately-held, development stage biopharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal disease. Relypsa's lead product candidate is RLY5016, a non-absorbed potassium binder for the management of hyperkalemia. Relypsa is dedicated to discover additional product candidates through use of its proprietary polymer platform.

InventisBio is a biotech company whose product pipeline includes small molecule drug candidates for targeted therapies in lung cancer, breast cancer and gout. The company is also actively developing drugs that can be combined with other immune-oncology targeted therapies, such as PD-1 antibody, for various cancer indications. The company is co-founded by Dr. Yaolin Wang and other scientists who have previously worked at Merck and Schering-Plough, leading various drug discovery projects in oncology, metabolic and infectious disease areas.

TELA Bio is a life science company that specializes in soft tissue reconstruction. The company aims to commercialize a portfolio of products that are purposefully designed to address a range of unmet needs in soft tissue repair.

BioShin is a wholly-owned subsidiary of Biohaven Pharmaceuticals, a public biotech company based in New Haven, CT, USA (NYSE:BHVN). BioShin is a clinical-stage biopharmaceutical company focused on developing medicines for the Asia-Pacific region. It has proven leadership from global industry and academic settings and a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, including rare disorders.

NextCure is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs. The Company is applying its proprietary platforms and know-how to identify novel and biologically relevant targets and develop first-in-class immunotherapy products.

PharmAbcine, Inc., a biotechnology company, develops human therapeutic monoclonal antibody (mAb) for the treatment of cancer and inflammatory diseases. It focuses primarily on the out-licensing of candidate therapeutics and clinical applications. The company develops TTAC0001, a human anti-angiogenic mAb against VEGFR-2(KDR); and dual specific antibody technologies, including DIG-body and PIG-body for therapeutic use. PharmAbcine, Inc. has a strategic partnership with Samsung Biologics Co.,Ltd. for the development and manufacturing of PMC-403 pipeline, a therapeutic antibody candidate to treat neovascular disorders. The company is headquartered in Daejeon, South Korea.

Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness. They have pioneered Micro-Invasive Glaucoma Surgery, or MIGS, in order to revolutionize the traditional glaucoma treatment and management paradigm. They launched the iStent®, their first MIGS device, in the United States in 2012. They are leveraging their platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. They believe the iStent® is the smallest medical device ever approved by the Food and Drug Administration, or FDA, measuring 1.0 mm long and 0.33 mm wide. In June 2015, they completed an initial public offering and their shares are now traded on the New York Stock Exchange under the ticker symbol “GKOS”. The company was founded in 1998 and is based in San Clemente, California.

Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. The company also develops a novel, a closed-loop solution that continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. Inspire Medical Systems, Inc. was founded in 2007 and is headquartered in Golden Valley, Minnesota.

Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives. The company's discovery process combines clinically validated biological targets and industry-leading chemistry to address the limitations of existing therapies. This approach allows us to efficiently and effectively develop precision oncology therapeutics that enhance overall patient well-being.

Arvinas is a pharmaceutical company that focuses on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Its proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body. The company was founded in 2013 and is headquartered in Connecticut, United States.

Synlogic is a biotechnology company that develops synthetic biotic medicines to perform metabolic functions to treat diseases. The company's lead programs target patients with rare genetic metabolic diseases, including phenylketonuria and secondary hyperoxaluria. Synlogic is also hard at work on synthetic biotics to address more prevalent conditions, including inflammatory bowel disease, cancer, and other metabolic conditions.

Aerpio Pharmaceuticals is a new, clinical-stage biotechnology company focused on the development of novel small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Aerpio was created in a spin-out transaction from Akebia Therapeutics to enable more rapid development of its exciting compounds. It is managed by the same successful team from Akebia, employing a similar outsourced approach to pharmaceutical development. Aerpio Pharmaceuticals was founded in 2011 and is based in Cincinnati, Ohio, United States.

Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.

Avanir Pharmaceuticals is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of their commitment, they have extensively invested in their pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones.

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was founded in 2017 and is headquartered in Boulder, Colorado.

Igenica, Inc., a biotherapeutic company, engages in the discovery and development of antibodies and antibody-drug conjugates for the treatment of cancer. The company focuses on the development of immunotherapies, functional antibodies directed to the tumor, and antibody-drug conjugates for the treatment of cancer. It provides IGN523, a humanized monoclonal antibody for the treatment of various hematologic and solid tumors; IGN786, an antibody-drug conjugate; and IGN381, an immune checkpoint target that plays a complimentary role in the tumor micro-environment to other known immune checkpoints. Igenica, Inc. has a strategic oncology research agreement with MedImmune. The company was founded in 2008 and is based in Burlingame, California. As of May 5, 2017, Igenica, Inc. operates as a subsidiary of Pierre Fabre Medicament SA.

NeurAxon, Inc. discovers and develops pain therapeutics targeting neuronal nitric oxide synthase. It has oral products in pipeline addressing acute migraine, neuropathic pain chronic daily headache, inflammatory pain, migraine prophylaxis, and severe pain. The company was founded in 2004 and is headquartered in Toronto, Canada.

ReViral is a developer of antiviral drugs designed to help patients and enlarge the antiviral market by developing novel first-in-class compounds. The company's antiviral drugs is a fusion inhibitor of RSV which is a highly potent, novel small molecule and is being developed to treat RSV in patients with severe disease including neonates, enabling patients to be treated who are infected with respiratory syncytial virus (RSV) by developing novel compounds.

ReViral is a developer of antiviral drugs designed to help patients and enlarge the antiviral market by developing novel first-in-class compounds. The company's antiviral drugs is a fusion inhibitor of RSV which is a highly potent, novel small molecule and is being developed to treat RSV in patients with severe disease including neonates, enabling patients to be treated who are infected with respiratory syncytial virus (RSV) by developing novel compounds.

Singulex, Inc., a biotechnology company, develops and commercializes direct molecular detection technology solutions. Its solutions enable life science researchers and clinicians to understand and manage disease. The company develops biomarker diagnostic systems that can detect and quantify normal and abnormal protein biomarkers. It is conducting pilot studies to validate Erenna BioAssay System, a digital molecule detection platform, which detects and quantifies molecule biomarkers in clinical samples. The company also offers various custom assay services, such as pilot study services, assay prototyping, assay characterization, and assay validation. The company was formerly known as BioProfile Corporation and changed its name to Singulex, Inc in September 2003. Singulex is based in Hayward, California

NextCure is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs. The Company is applying its proprietary platforms and know-how to identify novel and biologically relevant targets and develop first-in-class immunotherapy products.

NewMed Medical Co., Ltd. engages in the research, development, manufacture, and marketing of interventional artificial heart valve systems. Its products include artificial heart valves and transcather implantation systems. The company was founded in 2015 and is based in Shanghai, China.

SuperDimension is a privately-held medical device company that develops and markets minimally-invasive pulmonology devices that enable the diagnosis and potentially the treatment of distal lung disease. Our product line, the i·LogicTM System, includes both capital equipment and disposables, addressing a total available market of more than 8 million patients. Driven by our mission, "To be the world leader in the diagnosis and treatment of distal lung disease," we are focused on extending the capabilities of traditional bronchoscopy tools to help diagnose previously inaccessible lung lesions at an earlier stage when they may be easier to treat.

Miaoshou Doctor is a healthcare service platform for building an online communication service platform between patients and doctors. It helps healthcare professionals and patients to manage post-diagnosis outcomes and allows doctors to actively follow up with their patient's health through additional counseling and prescriptions. Tao He and Daoliang Han founded the company in 2015 and is based in Beijing, Beijing.

Keystone Heart aspires to be the world leader in embolic cerebral protection for cardiovascular procedures. To develop and manufacture cerebral protection devices, focused on protecting the brain from emboli to reduce the risk of brain infarcts during TAVR, AF ablation and other structural heart procedures. Cerebral function is the essence of quality of life. Preserving brain reserve throughout medical procedures is a key component to procedural success and patient care.

Cytek Biosciences provides solutions that enable scientists to rapidly, efficiently obtain deep biological insights through high quality, high parametric datasets. Cytek manufactures and supplies flow cytometry products and services. Cytek’s compact, affordable instruments, and wide-ranging support offerings are used by researchers and clinicians all over the world. Cytek is focused on accelerating the adoption of flow cytometry to fuel scientific discovery. These solutions deliver deep biological insights at an affordable price, provide high-end capabilities, and bring simplified workflows to more researchers than ever before.

ChemoCentryx focuses on discovery, development and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors. Their small molecule product candidates is designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.

Aragon Pharmaceuticals is a discovery-stage small molecule company focused on therapeutics for the treatment of hormone-resistant cancers, with an initial focus on prostate and breast cancer.

NeuroPace, Inc. designs, develops, manufactures, and markets implantable devices for the treatment of neurological disorders with responsive stimulation. It offers RNS System, a medical device that monitors and responds to brain activity. The company’s RNS System consists of a small implantable neuro stimulator that is connected to leads that are placed in up to two seizure onset areas. NeuroPace, Inc. was founded in 1997 and is based in Mountain View, California.

Arcutis Biotherapeutics is a privately held clinical-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology.

Biopharmaceutical company engaged in developing, manufacturing and commercializing novel biotherapeutics

InteKrin Therapeutics is a clinical-stage, privately held BioPharma company focused on developing and commercializing breakthrough therapeutics for neuroendocrine, metabolic, and immune disorders. Diseases such as diabetes, metabolic syndrome, and cancer are increasingly in need of novel treatments that provide patients with better treatment alternatives and help to curb soaring healthcare costs. The company is in the process of in-licensing early- and late-stage compounds that have the potential to unlock the complex hormonal relationship between metabolism, insulin resistance, and obesity.

Manipal Acunova Ltd. operates as a specialty contract research organization. It provides clinical development services, including project management, clinical development management, biostatistics, medical writing, bio-availability/bio equivalence, and central lab. The company provides bioavailability and bioequivalence services, including regulatory consultancy, volunteer screening, protocol development, pharmacokinetic analysis, adverse event reporting and emergency treatment, data management and statistical analysis, report writing and submission, and specimen storage and archival. It also offers clinical reference laboratory services comprising clinical testing lab for clinical trials, pharmacy company research testing, and patient testing services; and clinical trials and research services, including clinical operations, regulatory strategy and consulting, clinical monitoring, patient recruitment, and supply management services. The company's clinical management services include laboratory data management, SAS programming, ECG core labs, radiology and imaging, coding and dictionary management, pharmacovigilance, and PK/PD analysis. In addition, it provides site management services. The company offers research services for pharmaceutical, biotechnology, device, research, and diagnostic companies in Europe, North America, and Asia. Manipal Acunova Ltd. is based in Bangalore, India with additional offices in Frankfurt, the United Kingdom; Princeton, the United States; Mangalore and Manipal, India; and Moscow, Russia.

Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. The company’s preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains. It has a drug discovery collaboration agreement with Array BioPharma, Inc.; strategic partnership agreement with Illumina, Inc.; research collaboration agreement with Veracyte, Inc.; and strategic partnership agreement with Amoy Diagnostics Co., Ltd. and PREMIA Holdings (HK) Ltd. Loxo Oncology, Inc. was founded in 2013 and is headquartered in Stamford, Connecticut. Loxo Oncology, Inc. is a subsidiary of Eli Lilly and Company.

Cleave Therapeutics develops oncology pharmaceuticals designed to target neurodengeneration and pathways used by cancer cells to grow. The company is engaged in the discovery of novel, small-molecule drugs that affect protein-degradation pathways, upon which cancer cells depend for survival, enabling patients to get cured from cancer.

RedHill Biopharma, established in 2009, is a pharmaceutical company focused primarily on acquisition and development of late clinical-stage new, improved and patented formulations of existing drugs, with preference to a 505(b)(2)* regulatory paths, as well as acquisition and developement of late clinical-stage, new and patented orphan drugs.

Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that pointedly address long-standing unmet needs in oncology. Guardant is backed by Sequoia Capital, led by a seasoned management team comprising thought leaders and successful serial entrepreneurs in next-generation sequencing and rare-cell diagnostics and is closely advised by an oncologist-led medical steering committee from leading cancer centers across North America and abroad.

Aerin Medical Inc. develops non-invasive treatment solutions to improve nasal breathing disorders. It offers VivAer procedure for treating nasal obstruction; and RhinAer procedure for chronic rhinitis. The company also provides VivAer Stylus for nasal airway obstruction; and RhinAer Stylus for chronic rhinitis. The company was incorporated in 2011 and is based in Sunnyvale, California.

Atox Bio is a biotechnology company that specializes in infectious diseases, immunomodulators, and critical care.It focuses on novel modulators of the immune response that target key multiple and interrelated pathways of both the adaptive and innate immune response that play critical roles in infectious and inflammatory diseases as well as ischemia/reperfusion injuries. The company was founded in 2003 and headquartered in HaMerkaz, Israel.

Synlogic is a biotechnology company that develops synthetic biotic medicines to perform metabolic functions to treat diseases. The company's lead programs target patients with rare genetic metabolic diseases, including phenylketonuria and secondary hyperoxaluria. Synlogic is also hard at work on synthetic biotics to address more prevalent conditions, including inflammatory bowel disease, cancer, and other metabolic conditions.

At Affimed, they are committed to improving outcomes for patients with cancer. Their scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unqiue approach to fighting cancer. With their unparalleled expertise in innate immunity and innate cell engager-based medicines, they aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.

Rongchang Pharmaceutical has grown into a modern pharmaceutical company enterprise integrating the r$d,production and sales of modern chinese medicine and biological drugs.

Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Therachon is headquartered in Basel, Switzerland, with research labs in Nice, France.

Adimab's integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and expressability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.

Turning Point Therapeutics, Inc. is a clinical-stage structure-based drug design company for the discovery and development of precision medicines for cancer and other diseases. We are focusing on the design of novel chemical identities for established oncogene drivers with secondary resistant mutations, newly identified disease-driven targets, and potential targets regulating tumor microenvironment and tumor immunity.

Tricida, Inc. is a late-stage pharmaceutical company focused on the development and commercialization of its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. Metabolic acidosis has been associated with increased muscle wasting, loss of bone density and death.

TigerConnect is a provider of clinical communication solutions, TigerConnect helps physicians, nurses, and other staff communicate and collaborate more effectively, accelerating productivity, reducing costs, and improving patient outcomes. Trusted by more than 4,000 healthcare organizations, TigerConnect maintains 99.99% uptime and processes over 10 million messages each day. Its category-leading product innovations and advanced integrations with critical hospital systems deliver high value for hospitals and large health systems. Their commitment to client success is reflected in their broad support organization that works directly with clients at every stage to streamline communication workflows and achieve the highest possible ROI. The company was incorporated in 2010 and is headquartered in Santa Monica, California.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The company’s extensive expertise in product development has been built over the past 20 years: initially as a stand alone development organization, then as a U.S. subsidiary of Shire plc and, upon its acquisition of substantially all the assets of Shire Laboratories Inc. in late 2005, as Supernus Pharmaceuticals. The company is developing several product candidates in neurology and psychiatry to address large market opportunities in epilepsy, ADHD and depression. In addition to its two ADHD product candidates, Supernus is developing two late stage epilepsy product candidates, SPN-538 (extended release topiramate), and Epliga® (extended release oxcarbazepine).

Relypsa, Inc. is a privately-held, development stage biopharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal disease. Relypsa's lead product candidate is RLY5016, a non-absorbed potassium binder for the management of hyperkalemia. Relypsa is dedicated to discover additional product candidates through use of its proprietary polymer platform.

Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns. Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called Lung EpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel.

Sonendo developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science®. The GentleWave® System shows significant improvements in clinical efficacy and practice efficiency when compared to standard root canal treatment.1,2, 3 Sonendo is the parent company of TDO® Software, the developer of the most widely used endodontic practice management software in the world, designed to simplify practice workflow. TDO software seamlessly integrates practice management, imaging, social media, referral reporting, CBCT imaging, and offers built-in communication with the GentleWave System.

Acutus Medical develops medical technologies to treat complex cardiac arrhythmia. The company's platform displays the heart’s true activation pattern, turning the chaos of a complex arrhythmia into a clear vision for electrophysiologists. Acutus Medical is a privately funded company founded in 2011 and based in Carlsbad, California. Its products are co-developed in the U.S. and Europe with an exceptional team of medical scientists, biomedical engineers, and other professionals. It was founded in 2011 and headquartered in Carlsbad, California.

VectivBio is a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases. They are committed to pursuing rare diseases with well-defined biology that can be targeted with best-in-disease therapies that have the potential to meaningfully transform and improve the lives of patients and their families, not just provide an incremental improvement or benefit over the standard-of-care. It was founded as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia. VectivBio was incorporated in 2019 and is based in Basel, Switzerland.

Onyx Pharmaceuticals is a biopharmaceutical company committed to improving the lives of people with cancer. Their lead product is Nexavar (sorafenib), a novel, oral multiple kinase inhibitor that targets proteins involved in both tumor cell proliferation and angiogenesis.

Wuhan Eyegood Ophthalmic Hospital offers ophthalmology services. The company was founded in 2003 and is based in Wuhan, China.

CoreMap, Inc. develops a diagnostic technology for electrophysiologists for treating atrial fibrillation. It offers CoreMap micro-electrode solution for mapping tissue properties (ability to map sequentially). The company also provides CoreMap ultra-high resolution electrodes reveal the details of activation despite fibrillation. The company was incorporated in 2016 and is based in Winooski, Vermont.

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in phase II clinical trial for the treatment of frontotemporal dementia disease; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. The company also offers AL002 and AL003, which are in phase 1b clinical trial for the treatment of Alzheimer’s disease. In addition, it has 10 programs under research and development stage. The company has a collaboration agreement with Adimab, LLC for the research and development of antibodies. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.

Kinnate Biopharma develops precision oncology therapeutics to treat patients with genomically-defined cancers. Its mission is to expand the reach of targeted therapeutics by developing products for underserved populations. The company utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine. Its programs include candidates in preclinical development for cancers that are driven by specific oncogenic alterations in either the BRAF kinase gene or in the FGFR2 and FGFR3 kinase genes.

Biopharmaceutical company engaged in developing, manufacturing and commercializing novel biotherapeutics

Sonendo developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science®. The GentleWave® System shows significant improvements in clinical efficacy and practice efficiency when compared to standard root canal treatment.1,2, 3 Sonendo is the parent company of TDO® Software, the developer of the most widely used endodontic practice management software in the world, designed to simplify practice workflow. TDO software seamlessly integrates practice management, imaging, social media, referral reporting, CBCT imaging, and offers built-in communication with the GentleWave System.

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer.

MDClone Ltd. designs and develops software that analyzes medical records. Its software platform creates synthetic medical records for fictitious patients, avoiding the risk of public disclosure of actual medical data. The company’s platform enables researchers to examine the behavior of the disease, doctors, drugs, and health organizations without risking private patient medical data. MDClone Ltd. was founded in 2016 and is based in Beersheba, Israel.

Otonomy was founded in 2008 by Avalon Ventures and experts in the otology field in order to build the premier company dedicated to the treatment of otic disorders via localized drug delivery. This approach has already been widely adopted for the delivery of short-acting antibiotics to treat otitis media through a tympanostomy tube. In addition, otolaryngologists have demonstrated that the injection of steroids into the middle ear cavity can provide a therapeutic effect for patients with acute inner ear disorders such as Ménière’s disease and sudden sensorineural hearing loss. Expansion of this effort holds great promise for the treatment of chronic hearing loss, severe vertigo, and even tinnitus. The key to Otonomy's leading position in this nascent field is the development of a proprietary formulation platform that provides sustained drug exposure from a single administration. Broad application of this technology has already been established across a number of therapeutic classes and from these, three product candidates have been advanced into development.

Established in 2001, Eddingpharm’s vision and mission has always been to become China's leading supplier of patented drugs and branded drugs, bridge the gap between Chinese patients and global high quality medicines. They constantly acquired classic branded medicines from MNCs, that benefits Chinese patients through our effective operation cost management and expansion to the low-tier medical terminals. On the other hand, they keep exploring and innovating. Eddingpharm continuously introduce abroad patented drugs to China market, participate in international multi-center clinical trials and strive to realize simultaneous launch of new drugs in China and globally, providing physicians with more treatment options. Over the past few years, they rapidly expanded our business and strategically deployed resources in various fields. They are upgrading to a whole-industry-chain entity from sole in-licensing R&D and commercialization. Eddingpharm has nearly 1,000 professional representatives in 30 provinces across the country, with coverage of 19,000+ hospitals and 20,000+ pharmacies. Over the years, they have collaborated with multinational pharmaceutical companies, specialty pharmaceutical companies and leading R&D institutions to enrich our product portfolio by in-licensing patented drugs, setting up JV, gaining exclusive distribution rights and forming strategic alliances. Our focused therapy areas have been expanded to anti-biology, oncology, respiratory, cardiovascular and renal diseases. In addition, our several new drugs under development or regulatory registration are expected to be launched in the near future. The revolutionary product Vascepa® capsule is a single-molecule prescription product consisting of the icosapentaenoic acid commonly known as EPA in ethyl-ester form. Its ability has been verified that lowering triglyceride levels in relevant patient populations without raising LDL-cholesterol levels. The ability of reducing residual cardiovascular risk in patients with statin-managed LDL-C cholesterol, but persistent elevated triglycerides, has been published in The New England Journal of Medicine in November 2018. Additional results and analysis of total recurrent events observed were subsequently published in the Journal of American College of Cardiology in March 2019. Recently, supplemental new drug application (sNDA) for Vascepa® capsules reducing cardiovascular risks has been accepted for filing and granted Priority Review designation by the US FDA. Eddingpharm has been granted the rights of development, commercialization and supply of VASCEPA® in mainland China, Hong Kong, Macau and Taiwan since 2015, also including the management and sponsor of pivotal clinical trials for registration. They have completed a pharmacokinetic (PK) study in China and a racial comparison study of PK characteristics between Chinese and American healthy subjects. Phase III clinical trial is currently in progress. "Professionalism, excellence, responsibility, and persistence" are the values of Eddingpharm. Our profession is related to life and health, professionalism is the fundamental principle. Excellence runs through every minute of our work. Responsibility is our attitude towards each task. In the face of our beliefs and missions, they will stick to persistence and never give up. They are moving towards the goal that Chinese patients benefit from the world's best medicines and cutting edge medical technology.

Cerapedics, Inc., an orthobiologics company, develops and commercializes its proprietary synthetic small peptide technology platform. It offers i-FACTOR, a peptide enhanced bone graft in orthopedics that incorporates a small peptide as an attachment factor to stimulate the natural bone healing process; and i-FACTOR+ MATRIX for surgical implantation. Cerapedics, Inc. was founded in 2000 and is headquartered in Westminster, Colorado with an additional office in Denver, Colorado.

RDD Pharma, Ltd. operates as a pharma company, which engages in the development and commercialization of therapeutics for anotectal diseases and gastrointestinal disorders. It develops targeted pharmacological treatments for diseases of the anorectal region, such as anal fissures, fecal incontinence, and pruritus ani. The company was founded in 2008 and is based in Tel-Aviv, Israel with an additional office in New York, New York. As of April 30, 2020, RDD Pharma, Ltd. operates as a subsidiary of Innovate Biopharmaceuticals, Inc.

At Affimed, they are committed to improving outcomes for patients with cancer. Their scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unqiue approach to fighting cancer. With their unparalleled expertise in innate immunity and innate cell engager-based medicines, they aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.

Whale Imaging Inc. manufactures medical devices, including surgical imaging systems and ultrasound systems. The company offers products, such as G-Arm Products, including G-Arm B6 Duo, and G-Arm GXi 2; and Portable Ultrasound, including Lambda P9, and Sigma P5. It also provides training, preventative maintenance, and support services. Imaging Inc. was incorporated in 1998 and is based in Waltham, Massachusetts with its marketing and Research and Development (R&D) facilities at Boston, Massachusetts.

A peloton is a team of bicyclists who achieve great efficiency of motion through cooperative action. It is also the root of platoon, a nimble military unit with capabilities that exceed the sum of its component parts. Founded by Chairman of Biochemistry Steven L. McKnight of UT Southwestern Medical Center, Peloton Therapeutics represents a unique combination of innovative science, strong financial support from the Cancer Prevention Research Institute of Texas (CPRIT), and seasoned investors and management. Working in close collaboration with scientists at UT Southwestern, Peloton is advancing a promising discovery and development pipeline, comprised of several small molecule-based programs, each with a distinct target and mechanism of action. Peloton's vision is to become a major biotech company in Dallas with a passion for discovering and developing novel cancer drugs.

Natera is driven by a passion for elevating the science and utility of prenatal testing. The advent of the Information Age has created a paradigm shift in the fields of computing and informatics. Surprisingly, medical diagnostics have been slow to integrate these advances into genetic testing.

Nuvation Bio Inc., a biopharmaceutical company, focuses on the development of therapies for oncology. Its portfolio includes various oncology programs with multiple drug development candidates. Nuvation Bio Inc.was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. The company was founded in 2018 and is based in New York, New York with an additional office in San Francisco, California.

ARMO Biosciences is a biotechnology company that develops immune modulatory biologic therapeutics. The company is based in Redwood City, California.

Peptimmune is a privately held clinical stage biotechnology company focused on utilizing both novel and proven technologies to improve the therapeutic management of chronic autoimmune and metabolic disorders. The company is developing second generation therapeutics that are expected to result in safer and more effective products for obesity, multiple sclerosis, rheumatoid arthritis and pemphigus vulgaris.

Promentis Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of neuropsychiatric disorders. The company develops SXC-2023 and other compounds that engage System xc-, a central nervous system (CNS) target addressing glutamatergic imbalance and oxidative stress, to treat impulse control disorders, obsessive-compulsive disorder, and other neuropsychiatric diseases. Promentis Pharmaceuticals, Inc. was founded in 2006 and is based in Milwaukee, Wisconsin.

Aragon Pharmaceuticals is a discovery-stage small molecule company focused on therapeutics for the treatment of hormone-resistant cancers, with an initial focus on prostate and breast cancer.

Repare Therapeutics is a developer of oncology drugs designed to target specific vulnerabilities of tumor cells. The company's drugs combine a proprietary high throughput gene-editing and target discovery method with high-resolution protein crystallography, computational biology and clinical informatics, enabling patients to improve cancer treatment both with single therapy and in combination with existing drugs and treatments.

Roka Bioscience is dedicated to developing rapid, highly accurate molecular assays and instrument systems for the Food Safety Industry. Its newly released Atlas System represents a new tier of molecular rapid pathogen testing, offering automation and technology that bring true walk-away convenience and workflow advantages to the laboratory. Roka is focused on creating novel testing solutions that help manufacturers mitigate risks, protect their brands, and meet the increasing testing demands now and for years to come.

As of August 20, 2008, SGX Pharmaceuticals, Inc. was acquired by Eli Lilly & Co. SGX Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of therapeutics for addressing unmet medical needs in oncology. The company's product pipeline includes drug candidates from its FAST drug discovery platform, which uses X-ray crystallography and complementary biophysical and biochemical methods, combined with medicinal and computational chemistry. Its drug development programs target the c-MET receptor tyrosine kinase (MET), an enzyme implicated in an array of cancers; and the BCR-ABL tyrosine kinase enzyme for the treatment of chronic myelogenous leukemia (CML), a bone marrow cancer. Under the MET development program, the company develops SGX523, which is in Phase I clinical development studies for solid tumor indications; and SGX126, a preclinical development product for solid tumors indications. Under the BCR-ABL Development Program, SGX Pharmaceuticals develops SGX393, an oral therapy for the second-line treatment of CML, which is in preclinical development studies. Its drug discovery technologies are also applied to a portfolio of oncology targets, including JAK2, a non-receptor tyrosine kinase involved in cytokine-induced signaling and growth regulation, survival, and differentiation of cells; RAS, a protein that regulates cell growth; and three other tyrosine kinases. The company has a license and collaboration agreement with Novartis Institutes for Biomedical Research, Inc., Cystic Fibrosis Foundation Therapeutics, Inc., National Institutes of Health, and Eli Lilly & Company. SGX Pharmaceuticals, formerly known as Structural GenomiX, Inc., was founded in 1998 and is headquartered in San Diego, California.

cCAM Biotherapeutics Ltd., a clinical stage company, engages in the discovery and development of novel immunotherapies to treat cancer. It offers CM-24, a humanized anti CEACAM1 monoclonal antibody that inhibits the immunosuppressive effect of CEAC AM1 for the treatment of advanced or recurrent malignancies, including melanoma, non-small-cell lung, bladder, gastric, colorectal, and ovarian cancers. cCAM Biotherapeutics Ltd. was founded in 2010 and is based in Misgav, Israel. As of July 31, 2015, cCAM Biotherapeutics Ltd operates as a subsidiary of Merck & Co. Inc.

Bonovo Orthopedics, Inc. provides the latest orthopedic products to the Chinese healthcare community. Bonovo has over 15 years of experience manufacturing and distributing orthopedic products throughout China. Bonovo's unique relationships with leading clinicians and hospitals makes Bonovo an ideal partner for access to the Chinese orthopedic market.

Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.

Natera is driven by a passion for elevating the science and utility of prenatal testing. The advent of the Information Age has created a paradigm shift in the fields of computing and informatics. Surprisingly, medical diagnostics have been slow to integrate these advances into genetic testing.

Evox Therapeutics Limited develops a modular platform for clinical translation of exosome-based therapeutics. The company develops extracellular vesicles-based nucleic acid and protein delivery technology. Its technology aims to hitch a ride on tiny particles called exosomes, which the body uses to transport molecules between cells. Evox Therapeutics Limited was founded in 2016 and is based in Oxford, United Kingdom.

Relypsa, Inc. is a privately-held, development stage biopharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal disease. Relypsa's lead product candidate is RLY5016, a non-absorbed potassium binder for the management of hyperkalemia. Relypsa is dedicated to discover additional product candidates through use of its proprietary polymer platform.

Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Therachon is headquartered in Basel, Switzerland, with research labs in Nice, France.

Clementia is a clinical-stage company innovating treatments for people with ultra-rare bone disorders. The company develops disease-modifying treatments for patients suffering from debilitating bone and other diseases with a high unmet medical need. The company's lead product candidate, palovarotene, is an oral small molecule that has shown potent activity in preventing abnormal new bone formation as well as fibrosis in a variety of tissues. Clementia Pharmaceuticals was founded in 2012 and is headquartered in Montréal, Quebec.

Symbiomix Therapeutics, LLC operates as a biopharmaceutical company. It offers Solosec (secnidazole) oral granuels, formerly known as SYM-1219, a 5 nitroimidazole antibiotic which is an anti-infective drug for oral one and done treatment. The company provides medicines for bacterial vaginosis (BV) gynecologic infections. Symbiomix Therapeutics, LLC was incorporated in 2012 and is based in Newark, New Jersey with additional offices in Baltimore, Maryland and Hamden, Connecticut. As of October 11, 2017, Symbiomix Therapeutics, LLC operates as a subsidiary of Lupin Inc.

Alphamab Oncology is a clinical-stage biopharmaceutical company dedicated to the discovery, development manufacturing and commercialization of world-class innovative therapeutics for cancer treatment with multiple in-house proprietary platforms in bispecifics, protein engineering and antibody screening, Alphamab Oncology has built a robust pipeline in oncology/ immunology, and they are striving to develop next-generation or best-in-class medicines to address unmet medical needs globally.

TytoCare Ltd. develops handheld devices and application that connects people with doctor for an on-demand medical exam, diagnosis, and prescription if needed, anytime, and anywhere. The company’s tools help in examining the heart, lungs, skin, ears, throat, abdomen, and body temperature, and diagnose and treat various common conditions, such as ear infections, cold and flu, fever, headaches, eye irritation, congestion, sinus pain, allergies, sore throat, coughs and upper respiratory issues, bug bites and rashes, constipation, and stomachaches. TytoCare Ltd. has a strategic partnership with Novant Health. The company was incorporated in 2011 and is based in Netanya, Israel with an additional office in New York, New York.

ViewRay, Inc. designs, manufactures, and markets radiation therapy systems. The company offers MRIdian, a magnetic resonance image guided radiation therapy system to image and treat cancer patients. Its MRIdian integrates MRI technology, radiation delivery, and proprietary software to see the soft tissues, shape the dose to accommodate for changes in anatomy, and strike the target using real-time targeting throughout the treatment. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. markets its MRIdian through a direct sales force and distribution network. It has operations in the United States, France, Germany, and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

Medical device and pharmaceutical company advancing the science and technology of corneal cross-linking

Singulex, Inc., a biotechnology company, develops and commercializes direct molecular detection technology solutions. Its solutions enable life science researchers and clinicians to understand and manage disease. The company develops biomarker diagnostic systems that can detect and quantify normal and abnormal protein biomarkers. It is conducting pilot studies to validate Erenna BioAssay System, a digital molecule detection platform, which detects and quantifies molecule biomarkers in clinical samples. The company also offers various custom assay services, such as pilot study services, assay prototyping, assay characterization, and assay validation. The company was formerly known as BioProfile Corporation and changed its name to Singulex, Inc in September 2003. Singulex is based in Hayward, California

Arvinas is a pharmaceutical company that focuses on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Its proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body. The company was founded in 2013 and is headquartered in Connecticut, United States.

Rejuvenon a biopharmaceutical company committed developing and commercializing promising compounds for treatment of oncologic diseases.

Galecto, Inc. develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company, founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.

SteadyMed Ltd. is a medical-device company pursuing innovative devices for delivering injectable therapeutic drugs for pain relief, diabetes and other chronic conditions. The company's products are pre-filled drug-infusion patches that will be sold in conjunction with a series of pharma and device companies. Specific applications of the device will be tailored in accordance with the requirements of the company's partners.

Cerexa is a biopharmaceutical company focused on the development of a portfolio of novel anti-infective therapies for the treatment of serious and life-threatening infections. The company’s product portfolio includes Ceftaroline AcetateCeftaroline, an injectable cephalosporin that is used for the treatment of bacterial infections caused by gram-positive and gram-negative pathogens.

Cullinan Oncology is a developer of an externally sourced cancer therapeutics intended to end a drug program quickly if the early research suggests it won't work. The company's therapeutics are developed via assets sourced internally through dry lab or externally through business, academic and pharma collaborations, enabling researchers to get a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model.

ViewRay, Inc. designs, manufactures, and markets radiation therapy systems. The company offers MRIdian, a magnetic resonance image guided radiation therapy system to image and treat cancer patients. Its MRIdian integrates MRI technology, radiation delivery, and proprietary software to see the soft tissues, shape the dose to accommodate for changes in anatomy, and strike the target using real-time targeting throughout the treatment. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. markets its MRIdian through a direct sales force and distribution network. It has operations in the United States, France, Germany, and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

Chinook Therapeutics is a biotechnology company that specializes in the fields of therapeutics and life science. The company focuses on developing precision medicines for kidney diseases. Its services offers utilization of novel translational platforms and patient stratification tools, and emergence of accelerated regulatory pathways based on surrogate endpoints. The company was founded in 2019 and headquartered in Alberta, Canada.

Kalidex Pharmaceuticals, Inc. manufactures pharmaceuticals. The company was incorporated in 2010 and is based in Menlo Park, California.

ARYx is a product-driven pharmaceutical company with leading expertise and significant intellectual property in the area of retrometabolic drug design. They are focused on improving the safety of oral therapies for chronic disease.

Syndax Pharmaceuticals is a clinical-stage pharmaceutical company that focuses on an HDAC inhibitor for solid tumors and hematological tumors. It offers therapies to treat solid tumors and lung, breast, and hematological cancer. The company is developing axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor, in development for chronic Graft versus Host Disease, and entinostat, a class I HDAC inhibitor. Syndax Pharmaceuticals pipeline includes and SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, in development for the treatment of patients with MLLr and NPM1 acute leukemias.

Aspen Neuroscience, Inc. develops induced pluripotent stem cells to treat neurological conditions. Its products pipeline includes ANPD001, an autologous neuron replacement therapy in sporadic Parkinson disease; and ANPD002, a gene-edited autologous neuron replacement therapy for familial forms of Parkinson disease. The company was incorporated in 2018 and is based in San Diego, California.

Athenex focuses on the development and commercialization of therapies for cancer and immunomodulatory diseases. Its mission is to become a global leader in bringing innovative cancer treatments to the market and improve health outcomes. The company was founded in 2003 in Buffalo, New York, and has since grown to have operations across the U.S., China, Hong Kong, Taiwan, and the U.K.

Sonendo developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science®. The GentleWave® System shows significant improvements in clinical efficacy and practice efficiency when compared to standard root canal treatment.1,2, 3 Sonendo is the parent company of TDO® Software, the developer of the most widely used endodontic practice management software in the world, designed to simplify practice workflow. TDO software seamlessly integrates practice management, imaging, social media, referral reporting, CBCT imaging, and offers built-in communication with the GentleWave System.

ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The Company's technology enables targeting loss-of-gene features of solid tumor cells, sparing normal, healthy tissues.

Tisbury Pharmaceuticals, Inc. discovers, develops, and commercializes therapy to treat primary open angle glaucoma. The company's clinical candidate, R-801, accelerates flow via the trabecular meshwork via redox catalysis and K+-ATP (channel activation). The company was incorporated in 2017 and is based in Beverly, Massachusetts.

Clover Biopharmaceuticals is a global, clinical-stage, research-based biotechnology company focused on discovering, developing and commercializing transformative biologic therapies, with a focus on oncology and autoimmune diseases. Clover is utilizing its proprietary Trimer-Tag© technology platform to develop novel biologics targeting trimerization-dependent pathways. Additionally, Clover is leveraging its in-house cGMP biomanufacturing capabilities to develop select biosimilars.

Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism.

InteKrin Therapeutics is a clinical-stage, privately held BioPharma company focused on developing and commercializing breakthrough therapeutics for neuroendocrine, metabolic, and immune disorders. Diseases such as diabetes, metabolic syndrome, and cancer are increasingly in need of novel treatments that provide patients with better treatment alternatives and help to curb soaring healthcare costs. The company is in the process of in-licensing early- and late-stage compounds that have the potential to unlock the complex hormonal relationship between metabolism, insulin resistance, and obesity.

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company’s second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.

Iovance Biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). Under a collaborative research and development agreement with Dr. Steven A. Rosenberg at the National Cancer Institute, we are investigating our our lead product candidate, LN-144, in the treatment of stage 4 metastatic melanoma. In clinical trials, LN-144 has demonstrated curative potential in patients with metastatic melanoma, and it may also be applicable to a wide range of other solid tumors.

Imara, Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. It develops IMR-687, which is an oral, once-a-day therapeutic for the treatment of sickle cell disease and b-thalassemia. The company was founded in 2016 and is headquartered in Boston, Massachusetts.

Amphora Discovery Corporation operates as a biotechnology company. It provides integrated services to the pharmaceutical industry. The company's products and services include in vitro assay protocols, in vitro throughput screening and compound profiling services, custom assay development, enzymology services, and lead discovery/lead optimization partnering programs. It offers drug discovery contract research services, HTS, profiling and lead generation, and lead optimization solutions. The company serves pharmaceutical and biopharmaceutical companies, emerging biotechnology companies, and research foundations. Amphora Discovery Corporation was founded in 2001 and is headquartered in Durham, North Carolina. As of July 2008, Amphora Discovery Corporation operates as a subsidiary of Nanosyn Inc.

Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives. The company's discovery process combines clinically validated biological targets and industry-leading chemistry to address the limitations of existing therapies. This approach allows us to efficiently and effectively develop precision oncology therapeutics that enhance overall patient well-being.

Who we are - India's most convenient online pharmacy Netmeds.com, India Ki Pharmacy, is brought to you by the Dadha & Company – one of India’s most trusted pharmacies, with over 100 years’ experience in dispensing quality medicines. At netmeds.com, we help you look after your own health effortlessly as well as take care of loved ones wherever they may reside in India. You can buy and send medicines from any corner of the country - with just a few clicks of the mouse.

Avitide, Inc. discovers, manufactures, and supplies molecule-specific affinity purification solutions for the biopharmaceutical industry. It offers affinity separation technology that enables customers to achieve bioprocess development timelines, reduce program risk, predict commercial scalability, and reduce manufacturing costs. The company also develops affinity purification solutions for the manufacturing of life-saving therapeutics, including enzymes, novel scaffolds, multi-specific antibodies, gene therapies, and vaccines. Avitide, Inc. was incorporated in 2012 and is based in Lebanon, New Hampshire.

VelosBio, Inc., a biopharmaceutical company, develops novel antibody-drug conjugates (ADCs) to treat hematological cancers and solid tumors. The company develops cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). Its portfolio includes VLS-101, a ROR1-directed antibody-drug conjugate for patients with hematologic and solid tumor malignancies. The company was incorporated in 2017 and is headquartered in San Diego, California. As of December 18, 2020, VelosBio, Inc. operates as a subsidiary of Merck & Co., Inc.

Founded in March 2015, EUSA Pharma is a newly-established, profitable specialty pharmaceutical company with global reach from its headquarters in the UK and its commercial operations across Europe and the USA. Currently, EUSA Pharma has a portfolio of five approved as well as several named-patient specialty hospital products, including: Caphosol®, Xenazine®, Collatamp®, Custodiol® and Fomepizole® EUSA submitted the MAA for FOTIVDA (tivozanib HCL) as first line therapy for RCC in Q1 of 2016. EUSA Pharma has ambitious plans to expand its portfolio through acquisition and in-licensing and is led by an experienced management team with a strong record of building successful specialty pharmaceutical companies. The EUSA Pharma business is supported by significant funding raised from leading life science investor Essex Woodlands. In addition to direct commercial operations across the EU and US, EUSA Pharma also has a wide distribution network of commercial partners in Europe, the Middle East, Asia and Latin America and makes products available in approximately 40 countries across the world through this broad international platform.

Rapid Pathogen Screening, Inc., a biotechnology company, develops, manufactures, and markets point-of-care diagnostic tests for infectious diseases, inflammatory conditions, and bio-terrorism, and chemical nerve agent blood toxins. The company offers AdenoPlus, a clinical laboratory improvement amendments-waived point-of-care test that detects various known serotypes of adenoviral conjunctivitis to primary and urgent care professionals in the United States; and InflammaDry, a dry eye test to eye care professionals in the United States, and to various healthcare providers worldwide. It sells its products through distributors. Rapid Pathogen Screening, Inc. was founded in 2004 and is based in Sarasota, Florida.

Roka Bioscience is dedicated to developing rapid, highly accurate molecular assays and instrument systems for the Food Safety Industry. Its newly released Atlas System represents a new tier of molecular rapid pathogen testing, offering automation and technology that bring true walk-away convenience and workflow advantages to the laboratory. Roka is focused on creating novel testing solutions that help manufacturers mitigate risks, protect their brands, and meet the increasing testing demands now and for years to come.

Laekna Therapeutics Shanghai Co., Ltd. is a gene therapy company, which develops therapeutics for oncology and metabolic diseases. It develops pre-clinical discovery programs for oncology and liver diseases. It develops small molecule candidate LAE001 (previously known as CFG920) for prostate cancer. The company was founded in 2016 and is based in Shanghai, China.

I-Mab HK develops drugs to treat diabetes, cancer, and autoimmune diseases. The company develops preclinical compounds, including GX-P2; a long-acting PD-L1 drug for the treatment of inflammatory bowel diseases and GX-G8; a long-acting GLP-2 drug for the treatment of chemotherapy-induced diarrhea and short bowel syndrome. The company was formerly known as Tianzhenshi Biotechnology Company and changed its name to I-Mab HK in March 2017. The company is headquartered in Tianjin, China.

CrownBio is a Cutting Edge Translational Technology Company Making Precision Medicine a Reality CrownBio brings clarity to drug discovery around the world by helping biopharmaceutical companies solve some of today's most pressing challenges in oncology, cardiovascular, and metabolic disease Drug Discovery. Their premier Translational Platforms for cancer and metabolic disease help our clients accelerate their new drug development programs. CrownBio develops world-leading preclinical efficacy models and provides both in vitro and in vivo testing services and preclinical research products. They are a global company with facilities across the world in the United States, United Kingdom, China, and Taiwan.

Sikka Software Corporation is revolutionizing the retail healthcare industry via its platform cloud, analytical tools, apps and big data leadership. The retail industry includes over 2.1 million providers worldwide and over 600,000 in the United States. The Sikka Platform Cloud allows seamless compatibility with over 96% of the dental, veterinary, vision care and hearing care markets in the United States. Sikka Software Corporation platform cloud has over 17,000 installations with 94,000 providers and processes over 2 billion transactions a day and is experiencing strong growth and market presence in the retail healthcare big data space.

ViewRay, Inc. designs, manufactures, and markets radiation therapy systems. The company offers MRIdian, a magnetic resonance image guided radiation therapy system to image and treat cancer patients. Its MRIdian integrates MRI technology, radiation delivery, and proprietary software to see the soft tissues, shape the dose to accommodate for changes in anatomy, and strike the target using real-time targeting throughout the treatment. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. markets its MRIdian through a direct sales force and distribution network. It has operations in the United States, France, Germany, and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

IMMVIRA CO.,LTD, a biopharmaceutical company, develops a range of anti-cancer therapies based on genetically engineered viruses and augmented by cancer specific immune factors or chemotherapeutic agents. The company's product lines include oHSV encoding IL12 and anti-PD-1Ab (T3) to be administered by direct injection into the tumor mass; oHSV encoding IL12 only (T2) for use in combination with immune-modulators administered systemically; auxiliary therapies; and genetically engineered oHSV to infect tumor cells bearing unique receptors on their surface. IMMVIRA CO.,LTD was founded in 2015 and is based in Shenzhen, China.

Arteaus Therapeutics, LLC, a Cambridge, Massachusetts-based biotechnology development company focused on creating new therapies for migraine prevention.

Auxilium Pharmaceuticals (NASDAQ: AUXL) was founded in 1999 to develop and market pharmaceutical products that focus on urology and sexual health. While we remain dedicated to this founding principle, Auxilium’s mission has expanded to include the development and marketing of novel treatment options for many of society’s unmet medical needs.

Cleave Therapeutics develops oncology pharmaceuticals designed to target neurodengeneration and pathways used by cancer cells to grow. The company is engaged in the discovery of novel, small-molecule drugs that affect protein-degradation pathways, upon which cancer cells depend for survival, enabling patients to get cured from cancer.

SpringWorks Therapeutics is a biotechnology company that specializes in identifying, developing, and commercializing therapies for underserved patient populations suffering from severe rare diseases and cancer. The firm's pipeline product includes Mirdametinib, Nirogacestat, and others. The company was founded in 2017 and headquartered in Connecticut, United States.

CoGenesys is a biopharmaceutical company focused on the development of peptide- and protein-based medicines. The company develops peptide and protein-based medicines for cancer, cardiovascular, metabolic, infectious, autoimmune, and CNS diseases.

Ascendis Pharma has built a high value pipeline with the aim of changing clinical treatment paradigms. Using our innovative TransCon prodrug technology platform, we continue to identify new opportunities addressing areas of high unmet medical need. TransCon is applicable to all drug classes, and is currently being used to create superior prodrugs of proteins, peptides and small molecules. Depending on choice of TransCon Carrier, either systemic or localized drug exposure is achieved, while dosing frequency is determined by the choice of TransCon Linker. The prodrugs are new chemical entities with new patent life. Product development process is de-risked, as the prodrugs release the active component in its native and unmodified form, maintaining the original drug’s well known mode of action.

Ornim, Inc. develops medical monitoring tools for the measurement of blood flow and oxygen saturation in patients. The company offers CerOx, a non-invasive monitor, which provides real-time data on oximetry and blood flow measurements of specific tissue. Its products are used for applications in neurological treatments and cardiac surgery. The company was founded in 2004 and is based in Santa Clarita, California. It has a research and development subsidiary operation in Israel.

PMV Pharma is developing first-in-class p53 and p53 pathway modulators for the treatment of cancer. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.

ViewRay, Inc. designs, manufactures, and markets radiation therapy systems. The company offers MRIdian, a magnetic resonance image guided radiation therapy system to image and treat cancer patients. Its MRIdian integrates MRI technology, radiation delivery, and proprietary software to see the soft tissues, shape the dose to accommodate for changes in anatomy, and strike the target using real-time targeting throughout the treatment. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. markets its MRIdian through a direct sales force and distribution network. It has operations in the United States, France, Germany, and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

ViewRay, Inc. designs, manufactures, and markets radiation therapy systems. The company offers MRIdian, a magnetic resonance image guided radiation therapy system to image and treat cancer patients. Its MRIdian integrates MRI technology, radiation delivery, and proprietary software to see the soft tissues, shape the dose to accommodate for changes in anatomy, and strike the target using real-time targeting throughout the treatment. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. markets its MRIdian through a direct sales force and distribution network. It has operations in the United States, France, Germany, and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

Founded in March 2015, EUSA Pharma is a newly-established, profitable specialty pharmaceutical company with global reach from its headquarters in the UK and its commercial operations across Europe and the USA. Currently, EUSA Pharma has a portfolio of five approved as well as several named-patient specialty hospital products, including: Caphosol®, Xenazine®, Collatamp®, Custodiol® and Fomepizole® EUSA submitted the MAA for FOTIVDA (tivozanib HCL) as first line therapy for RCC in Q1 of 2016. EUSA Pharma has ambitious plans to expand its portfolio through acquisition and in-licensing and is led by an experienced management team with a strong record of building successful specialty pharmaceutical companies. The EUSA Pharma business is supported by significant funding raised from leading life science investor Essex Woodlands. In addition to direct commercial operations across the EU and US, EUSA Pharma also has a wide distribution network of commercial partners in Europe, the Middle East, Asia and Latin America and makes products available in approximately 40 countries across the world through this broad international platform.

Audentes Therapeutics is a biotechnology company committed to the development and commercialization of innovative new gene therapy treatments for people with serious rare diseases. We are a focused, experienced and passionate team driven by the goal of improving the lives of patients.

Molecular Staging, Inc., a life sciences tool company, develops technologies for the detection and measurement of proteins and nucleic acids. It provides technologies for proteomics, genomics, pharmacogenomics, and diagnostics applications. The company’s products and services include protein microarrays analogous to the DNA microarray, enabling researchers to study multiple proteins; whole-genome amplification that allows DNA samples as resources, enabling researchers to return to them for new tests or confirmatory diagnoses; and multiplexed diagnostics that enable earlier detection of disease.

VectivBio is a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases. They are committed to pursuing rare diseases with well-defined biology that can be targeted with best-in-disease therapies that have the potential to meaningfully transform and improve the lives of patients and their families, not just provide an incremental improvement or benefit over the standard-of-care. It was founded as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia. VectivBio was incorporated in 2019 and is based in Basel, Switzerland.

Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. Their lead peptide product candidate, setmelanotide, is a potent, first-in-class melanocortin-4 receptor (MC4R) agonist for the treatment of rare genetic disorders of obesity. They believe that setmelanotide, for which they have exclusive worldwide rights, has the potential to serve as replacement therapy for the treatment of melanocortin 4, or MC4, pathway deficiencies. The MC4 pathway is a compelling target for treating these genetic disorders because of its critical role in regulating appetite and weight, and peptide therapeutics are uniquely suited to activating this target.

Sonendo developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science®. The GentleWave® System shows significant improvements in clinical efficacy and practice efficiency when compared to standard root canal treatment.1,2, 3 Sonendo is the parent company of TDO® Software, the developer of the most widely used endodontic practice management software in the world, designed to simplify practice workflow. TDO software seamlessly integrates practice management, imaging, social media, referral reporting, CBCT imaging, and offers built-in communication with the GentleWave System.

Terns Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops molecularly targeted, oral, small-molecule drugs to treat cancer and liver diseases. Its products includes TERN-101, a potent non-bile acid farnesoid X receptor agonist and TERN-201, a semicarbazide-sensitive amine oxidase inhibitor. The company was founded in 2017 and is based in Foster City, California with additional offices in Shanghai, China.

ProteKt Therapeutics is a drug development company aiming to develop potent and selective oral inhibitors of the kinase PKR for the treatment of neurodegenerative and neuroinflammatory diseases. The company has raised a $4M pre-A round and graduated from the FutuRx accelerator in 2019.

Ikena Oncology is dedicated to bringing next generation oncology therapies to patients suffering from cancer. Ikena Oncology are committed to leveraging our unique understanding of the complex biologic pathways that drive the formation and spread of cancers to discover and develop novel, patient-directed therapies. Selecting patients for treatment in clinical studies with biomarkers we develop is at the core of our strategy.

LogicBio develops gene therapy vectors for previously incurable genetic and infectious diseases, including: hemophilia, HIV/AIDS and methylmalonic acidemia (MMA). Our proprietary technology based on the non-pathogenic Adeno-Associated Viral (AAV) vector offers superior efficiency and safety compared to all competitors on the market, and is uniquely suited for the treatment of children as well as adults.

Harbour BioMed is a developer of bio-therapeutics aimed at immuno-oncology and inflammatory diseases. The company engages in discovery and development programs that are centered around two patented transgenic mouse platforms for generating both fully human monoclonal antibodies (H2L2) and heavy chain only antibodies (HCAb) based immune cell engager (HBICETM) bispecific antibodies, thereby enabling medical professionals to generate potential therapeutic antibodies and accelerate drug discovery and development.

Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.